The clinical and molecular epidemiology of inherited colorectal cancer in Newfoundland and Labrador by Wish, Tyler



The Clinical and Molecular Epidemiology of Inherited 
Colorectal Cancer in Newfoundland & Labrador 
By 
Tyler Wish 
A thesis submitted to the school uf graduate s tudies in partial fulfillmen t of the 
requirements for the degree of Doctor of Philosophy (Medicine) 
Facul ty of Medicine 
Memorial University of Newfoundland 
November 2011 
St. john' s Newfoundland and Labrador 
Abstract 
Backgrolll1d 
Colorectal cancer (eRC) is a hereditary d isea~ and approximately one-third 
of all patients have a family history of CRe. A greater understanding of the 
clinical and molecular features associated with hl'reditary C I~C may It!ild to 
improved scrC<'ning ilnd patient outcomes_ Tht! purpo~ of this thesis is to 
investigate the clinica l, molecular <lnd environmental features that arc associatcd 
with CRC patients who have a family history of the disease. 
Methods 
ln cidt!nt population-based CRC patients from Newfoundland and Labrador 
were prospectively identified from the Newfoundland Colorectal Cancer 
Registry (NFCCR). Eligible index patients (n = 1,173) were diagnosd at less than 
75 years of age and eligible stl,d y control s (n -=0 i,6(3) were identified through 
random digit dialing. Consenting patients (n = 750) provided a blood silmple 
<lnd permission to access medic<ll records and tissue blocks. I:liologic<ll speci mens 
underwent molecular testing for germline mut,ltions in the mismatch repair 
genes (i.e. Lynch Syndrome), tumour micros<ltdlite-i nstabili ty and for the 
somatic p. V600E BRAF mutation. Patients <lnd controls complt! tt!d family history, 
person<ll history and food frequency questionnaires 
R(.'SlIi ts 
Thirty- two percent of index patients (n "" 179 / 553) had at least one first-
degree relative (FOR) affectt.>d by eRe. High-risk patients contained either a 
pilthogenic mismatch repai r gene variant (n "" 17), or s.1 tisfied high-risk family 
history criteria, defined by either the familial CRC type X (FCcrX) (n "" 15) or 
modified -FCCTX criteri., (n = (6), The risk of C RC in family members of patients 
identified as FCCTX and modified-FCcrX is si milar, bu t is signific.lntly less 
when compared to Lynch synd rome. Twenty-s ix percent of non high-risk 
p.1tients had .1t least one FOR affected by CRe. Patients who had dther a 
synchronous or metachronous tumour or a V600E 8RAF mutation tumour were 
associated with a significantly greater family history of Ci{C compared to 
patients without either of these features. ['Mients who have a V600E 8RAF 
mutation turnOUT are s ignifica ntly associMed with diabetes, smoking and 
inversely associated with non-steroidal anti-inflammatory drugs. 
Conell/siollS 
The incidence of hereditary colorectal cancer in NL is high. A small 
subgroup of patients sa tisfies high-risk criteri.l, but the etiology o f the dise.1SC is 
unknown fo r the majority of these families .1nd requires further inVl'stigation 
The V600E BRAF mut.1tion and the occurrence of multiple tumours are associ.,ted 
with an elevated family his tory of Ci~C and m.,y be llscfulmarkeTS of increased 
risk for screening purposes. Metabolic and inflammatory mechanisms may be 
important factors in the etiology of patients who have a 8RAF mutation tumour. 
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Chapter 1 - Introduction 
1.1 C% rectll/ Cllll cer 
Color~c t al ca ncer (CT{C) is th~ third most common C.1ncer and third le.1ding 
cause of c.1ncer-related mortality in the United States and Canada. The Iifl'limc 
probability of developing colorectal canc~r in Canada is f..'Stimat~d to be 7.1 % for 
males and 6.3% for females [1,2]. Age·standardized incident rates across Canada 
for the period 1994-2005 have been s table [2] ilnd mortality riltes continue to 
decline (1.3% per year for males and 1.7'", per yeilr for females) as a result of 
e"rlier d~tection and improvem~nts in treatment. Howev~r, ilg~-standardized 
incidence rates in the Province of Newfoundland and Labrador (NL) are 
increasing. Furthermor~, the Province has the highest incidence of colorectal 
ca ncer in th~ country ilnd colorectal Cilncer nlOrtillity rat~s in NL ilr~ 
approximiltcly twic~ those in British Columbia. These geographicill dispilritit..'S 
arc not fully understood, but may be related to differences in environment, 
famili.11 and genetic risk factors, and possibly related to differences in colorectal 
cancer screening participation ril tes. It is cI~ar. howeve r, that the diseilse 
represents il miljor public health bu rden for the Province and that further 
research isnecesS<l ry 
The molecular etiology of inherited colorectai can(t;'f is poorly understood 
Although numerous genetic risk factors have been link~d to coiorectal Cil ncer 
susceptibility, they explilin littl~ of the diseilse risk 13[. For a small proportion uf 
colorectil! cancer piltients «5'f,, ), who .1re .1ffecil'd by il known colorectal Cilncer 
syndrome (e.g. Lynch syndrome), the specific etiology is understood. However, 
the etiology remilins to be poorly understood for the 20% - 30% of colort'ctill 
Cil ncer piltients who ilppeilr to be il ffected by iln inherited predisposition ]3J. A 
grl'ilter understilnding of the etiology of inherited color('ctil l Cilncer will trmlslilte 
into bt!tter preventative strategies, improved piltient outcomes and enhanced 
utilizil tion of heillth c.1fe rt.-sources 
Colorectill cancer is il complex ilnd heterogenous dismS('. In the IWills 
Vogebtein proposed a model of carcinogenesis that suggested that the 
development of colorectal ca ncer was driven by the progressive and s tepwise 
accumulation of specific genetic al terations. The progressive ilccumuliltion of 
genl'lic ilnd epigenetic illteTiltions <lnd the erosion of the genome's integrity (i .e. 
genomic deletions, insertions, mutiltions ilnd rCilfTilngements) is believed to <l 
principill driver of coiorectal cilfcinogenesis, ,llld is refcrred to ilS gcnomic-
inst<lbility. Furthermore, the molecuiilf etiology of colorectill cilfcinogenesis is 
now recognized ilS heterogenous ,lnd results from ilt least three different 
molecular mechilnisms, which ilfe also rdcrred to as pathwilYs of cilrcinogenesis 
[4[ 
Many of the recent <ldv<lncements in ou r understilnding of colorectill 
carcinogenesis have .1risen from the emerging field of molecu lar pilthology 
epidemiology]5J. This field of study takes a tr,lnsdisciplinary approach and hilS 
numerous advant<lges over trilditionill epidemiologiml methods, pilfticulilrly 
when investigating complex and heterogenous diseases such ilS color('clal Cilncer. 
For this reason, the present study h;;JS tilken a molecular pathology <lpproach to 
the investigation of colored,l! cancer by simultilnl'Ously considering trilditional 
epidemiological risk factors (e.g. smoking) in conjunction with clinical and family 
history information, and molecular markers of carcinogenesis 
I'articipants fo r this research projl'Ct were recruited from Newfoundl,lnd, 
which is a valuable resource for the investigation of complex dis"aSl'S [6J . It is 
;llso an ideal region to investiga te the hereditary basis of co[orectJ[ cancer 
becJuse fJmi[ ics have tended to be IJrge over several generations, family 
members hJ ve sett[ed neJr the ancestral community, little in-or-out migrJtion 
has occurred s ince the initial settlements in the [ate eighteenth and l'Jrly-
nineteenth centuries [6[ Jnd J[so becJuse Newfoundland has the highest 
ineidence of inherited colorectal CJncer in the world [71. The Newfoundland 
population is also attractive from J mo[eculJr genetics perspective, as the 
population has the greatest generalizibility to Caucasian populJtions when 
compa red to twelve other founde r populations ]8 J. 
1. 2 /~ ('s('a rcli PurlJOSe 
The purpose of this thesis is to generate insight into the etiology of hereditary 
colorectal cancer, which can then be utilized to improve the effectivenl;!SS of 
colorectal cancer screening. The objectives are to investigate the: 
I. Clinical and molecular epidemiology of colorectal cancer 
2. Risk of developing colorectal cancer in first-degree family members 
according to family history criteria 
3. Pa tient and pa tient-tumour characteristics that are associated wi th 
colorectal cancer patients who have a family history of disease 
4 Dietary and lifestyle fa ctors a~soc ialed with colorectal ca ncer patients 
according 10 tumour-moleClilar phenotype 
Chapter 2 - Literature Review 
2.1 Colorecta l Crl ll cer Etiology 
2. ·I.lll1ll(."ri/('dColor~cI1lICi/IJca 
Well -defined inherited colorectal cancer (CRC) syndromes (e.g. l.ynch syndrome 
and polyposis syndromes) account for approximately 5% of all incident colorectal 
«UlCer patients [3J. Lynch syndrome is the most previllent inherited coloreet,,1 
c.lncer syndrome i1nd is chMilcterized by an devilted susceptibility to develop 
gastrainteslim!, gynecologicil!' brilin, skin and other rnalignilncies [9J. It is i1n 
autosomal dominilnt condition ca used by inactivilting germ line mutil tions of 
genes, MUll, MSH2, MSH6 and PMS2, which code for proteins thilt perform 
DNA mismatch repair (MMR). The two most prevalent polyposis syndroml!S are 
familial adenomatous polyposis (FAP) and i1ttenuilted £amiliill adenomatous 
polyposis (AFAP), both of which are caused by inactivilting mutations of the 
adel1omafOJ4$ polyposis coli (A PC) gene [10]. Although the number of polyps can 
range considerably for these two synd romes, patients affected by ei ther FAP or 
AFAP typically prl!Sent with numerous adenomatous polyps of the colon. 
Prophylactic management for these patients is necessary, as the lifetime risk of 
developing colorectal cancer is nearly one hundred percent for patients inheriting 
i1n APe mutation. MUTYH-associated polyposis (MAP) is also associated with 
the development of adenoma tous polyps, but is ca used by mutations of the 
ML/TYH gene, and is inher ited as an autosoma l recessive cond ition . 
The fMC hamartomatous polyposis syndromes are another subgroup of 
inherited colorectal cancer sy ndromes. These syndromes, which include Peutz-
Jeghers syndrome .lnd Juvenile polyposis syndrome, .. re c.lused by mutations of 
STKl1, SMAD4, and BMPRI A /10/. Then! .. re .. Iso rare syndromt.'S of unknown 
etiology thill Me associilled with the development of numerous hyperplastic 
polyps. The best example is known .1S hypl' rplastic polyposis syndrome (H I'S) 
These syndromes will be discussed in further detail. 
Based on the findings from kindred and twin studies 11 1-131, it is l'Stimated 
that 20% - 30% of all colorcctal cancer cases are d irectly attributable to inherited 
facto rs. TIlt.' relative contribution of gendic and environmental risk fnctors is 
unclenr, but inherited factors .. ppear to playa prominent role 113, [41. 
Unfortunntely, however, the specific etiology for these pnticnts is poorly 
understood. Newfoundland may h .. ve the highest incidence of inherited 
colorectal cnncer in the world. Green <'I al reported 171 that Newfoundland has a 
signific.lntly gre,ller incidence of pntients with at least one affected first-degree 
rdative (FDR) when compared to thirteen other population-based sludk-;; 
conducted worldwide. Furthermore, it was subsequently demonstrated 11511h .. t 
the high incidence of inherited colorect .. 1 c .. ncer in Newfoundl .. nd is not cntirdy 
.. ttribu t .. ble to founder mutalions in known susceptibility genes, which suggests 
Ih .. t Ihe high incidence of inheriled colorectal cancer in the province m .. y be 
caused by novel susceptibility f .. ctors. However, the high incidence of heredit.1TY 
coloreclal C.lnCer in Newfoundland may also be rdilled to increased 
clwironmental risk, founder effect~ in unknown genes, or a better ascertainment 
of family risk 17, 151 
2.1.3 G<'lldic Susceptibility 
2.1.3.1 Low-l'enetrililt Susceptibility Loci 
Accumulilting evidence indiciltes that the e tiology of colorectill Cilncer is 
complex ilnd heterogenol's. A recent analysis 1161 reported that ilS many as 170 
genetic variants may be implicated with colorectal Cilncer susceptibility. Genome-
wide associiltion stllJies (GWAs) hilve discovered mul tiple low-petlctrilnt loci 
that il re associated with coloredal susceptibility. To date, colorl'cta l Cilncer 
susceptibility is significantly associated with loci locilted i1t: 8q24 11 7, IHI, Hq23.3 
[191, IOpl41191, 11q23120l, ISql3 1211, and 18q21 [21, 221. A more recent mda -
analysis 1231 has identified four additional risk loci at: 14q22.2, 16q22.1,19qI3.1, 
and 20pI2.3. The~ findings arc consistent with thl;' common disease-common 
variant hypothesis 1241, which hypothl'sizes that common vari,lIlts are likely to 
underlie much of the disease susceptibility foc common diSC"ases. Unfortunately, 
however, the cancer risk associated with any single variant is sma ll and 
collectivl'iy these risk filctors account for only a small pecccnt,lge of the excess 
familial risk - approxinliltely 6% 123]. However, the risk conferred by thest' loci 
is likely to be a conservative estimate, since thl;' identified loci are often not the 
causative alleles, but loci thilt thilt Me in linkagl;' disequilibrium with the 
causative variant 
It is unlikely that additional common (minor allele frequency > 30%) low-risk 
variants will be discoverl;'d, as GWA shldies have been designed to have 
su fficient statistical power to identify these variants. It is probable, howevec, th'lt 
less common susceptibility alll'ies exist, some of which likely have greater 
penetrance. It may be possible to identify these illleles with d ifferent 
tcchnologiCilI and analytical approaches, such as exome or whole-genome 
scquencing. 
The mechanisms through which the identified risk alleles modify colorectal 
C,lIlCl.'r susceptibility arc largely unknown; particularly as many of the risk loci 
identified thus far are positioned at regions of the genome that lack protein-
cod ing transcripts. It has been hypothesized that some va riants may promote 
c.lllCer predisposition by inflm .. 'llCi ng gene expression at dbtant s ites. In support 
of this hypothesis, two recent studies [25, 26[ have provided evidence 
demonstrating how a particu lar variant (r-;6983267), which n..'S ides in a region 
lacking protein-coding transcripts, promotes colorectal ca rcinogenesis. One 
st udy [25[ suggests th.lt thl' risk-associilted variilnt ilt 8q24 (C-illlcle) physica lly 
inter.lCts with the MYC promoter, located 335kb ilWilY, to promote colorectal 
carcinogenesis by increasing expression of MYC. Another study [26[ propost.'S 
thilt the risk variilnt C.1 USCS genomic reilrrangemcnts ilround 8q24 and results in a 
copy number increase for a transcription-f.lCtor binding s ite thilt promott.'S 
colorectal carcinogenesis by over .. activation of the Wnt s ign.lling pilthwilY. While 
the definitive .1nswer is uncle.lT, these studit.'S hilve illuminiltcd mechilnisms 
through which non protein .. coding vilriilnts ITIily affect gene expression and 
promote carcinogenesis. 
Ct'netic studies using high-rbk families and affectt.'(1 s ib-pairs are strateg ies 
thilt have also identified loci ilssociil ted with colorcctal c,lnccr susceptibi li ty [27-
32 ]. For exa mple, a susceptibility locus has been identified at a region on 
chromosome 9q [27] ilnd lilter confirmed by ildditional s tudies [28, 29[. A 
genome wide s ib-pair analysis of 70 affected families [32J identifit'd susceptibility 
loci at 3'1 [30, 31 [ and at 7'131.31. The causative genes have yet to be identified. 
Nevertheless, the results support the hypothesis that multiple susceptibility 
al leles are implicated in colorectal cancer predisposition. 
],r}] /-oll'-P('lIclraIlIC(,lIclic Variall!.\' 
Low-penetrant gene variants are also linked with colorectal cancer 
susceptibi lity [33[. An example of a low-penetrant genetic variant is the 113V7K 
variant of the APC gene, which is associated with a 2 - fold increase in colorectal 
cancer risk and is present in approximately 6% of the Ashkenazi Jews [34[. The 
TCFBR1'6A vari,lllt is another example, and it confers a 1.2-fold increase in 
colorectal cancer risk which, although modest, may account for 3% of the total 
colorectal cancer burden [35[. Furthermore, the TGFBR1'6A risk a llele is more 
prevalent in high-risk families [361 and may be implicated in FCCTX [37]. It has 
recently been demonstrated [38[ that heterozygous A1UTYH mutiltion carriers are 
at a slightly increased risk for developing co[oreclal cancer (ildjusted Ol~, 1.41::\; 
95% Ci, 1.02 - 2.16), ilnd MUTYH is now recognized as a low-penetrant risk 
Gene Vilriants have also been identified as modifiers of (<lncer risk. The 
findings of two stud ies [39, 40] have suggested th'lt a 1'53 vari;;lllt has a significant 
effect on the age of ca ncer onset in Lynch synd rome patients, but il third study 
[41] found no such association. Other variants, such as /IRAS/'VNTR and 
MTHF!C677V, are sllspected of influencing colorecta l cancer risk, but their 
mechanism of action is unknown and fllrthe r s tudies are required [35] 
2.2 Colorectal Callcer Risk Factors 
2.2.1 Family History 
A family history of colorectal cancer is a significant risk factor for developing 
the disea,;e [12, 42-45]. A meta-analysis [43] of 27 case-control and cohort studies 
indic.lted that the relative risk (RR) for developing colorectal cancer w.1s 2.25 
(951<, Confidence Interval (CI), 2.00 - 2.53) if a first-degree relative was affected. 
The risk is significantly greater if more thiln one first-degree relatiVl' is affected 
(RR, 4.2; 95',7" CI, 3.01 - 6.08). Furthermore. the risk is greatest if a first-degree 
relative was affected before .. ge 45 years (RR, 3.87; 95% 0, 2.40 - 6.22) and 
reduces if diagnoses was between 45 - 49 years (RR, 2.25; 95% Cl, l.tl5 - 2.72) or 
greilter than 59 years age (1m, 1.82; 95'7<, CI,I.47 - 2.72). Having a first-degree 
relative affected with an adenom .. is .. Iso a significant risk factor (RR, 1.99; 95)1" 
Cl, 1.55 - 2.55), as is having a second-degrt!C reliltive ilffectt.-d by colorcctill Cilncer 
(RR, 1.73; 95% G,I .02 - 2.94) [44]. It has bto't!n reported [44,45] thilt the risk of 
colorectal ca ncer is greiltcr if il sibling is affected (RR, 2.79; 95% G, 2.36 - 3.29) 
rather thiln if a parent is affecll'd (I{R, 2.07; 95% CI, 1.83 - 2.34). Furthermore, it 
has also been reported [451 that the risk of colorecta! cancer is greatest in siblings 
of those with right-sided tumours 
2.2.2 EllvirOJllllt'lItll/ Risk Faciors 
In addition to genetiC filctors, numerous non-heritable factors ilre abo 
associilted with the risk of colorectal cancer. These include: dietary f,lCtors, the 
determinants and consequences of insulin resistance syndrome and smoking. 
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2. 2.2.1 DiermyFaclors 
Dietary factors have been implicated as colorectal cancer ri sk fac tors not 
only because of the physic<ll inter<lction with the digestive tract, but also because 
of the associa tion between the western-did and a hi gh incid ence of co1orl'ctal 
cancer. Although numerous dietary risk factors have been reported the find ings 
have often been conflicting. For example, a diet rich in fruits and \'egetables has 
been hypothesized to reduce colo recta l cancer risk b ut, in an analysis of 3 1 C<lse-
control s tud ies, only seventeen fou nd an <lssociation between the disease and low 
consumption of fruit and vegetabk's [46]. The consumption of meat products is 
also associated with colorectal cancer risk. [t is thought that meat cooked at high 
temperatures may contain carcinogenic heterocyclic am ines, polycyclic aromatic 
hyd rocarbons, and N-ni troso compounds [47]. However, two meta-ana lyses [48, 
49] investigating meat consumption h<lve found non-significant and inconsistent 
results. Sim ilarly, no clea r association has bet!n found betwt't'll a high-fat diet 
<lnd colorecta l cancer [50 [. A high-fiber diet \v<lS suggested to reduce colorectal 
ca ncer risk in <l large European coho rt study [51 ], bu t two addi tion<ll cohort 
stu d ies [52, 53] found no clear associa tion. Convt;'rsely, alcohol con~umption ha~ 
consistently been linked with a slight increase in the risk of colorecta l crmcer. In a 
pooled ana lySis of 8 cohort ~tud it;' ~ [54], alcohol use wa~ associa ted with a 
sign ific'l n tly devated risk of colorectal cancer (RR, 1.23; 93% CJ 1.07 - 1.42). 
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],],].] Lifestyle Fa('tor.\' 
Insulin rt'sistance syndrome (mS) - a lso known as metabolic syndrome - is 
caused by a defect in insu li n action (insulin rt'sistance) ilnd il compens,ltory 
increase in insulin secre tion (hyperinsulinemiil) [55[. It is associilted with a 
cluster of metilbolic ilbnormillities, including: obesi ty (pilrticularly visceral 
adiposity), impaired glucose tolerance, hypertriglyceridemiil, hypertens ion, type 
2 diabetes, and atherosclerotic cardiovascular disease. According to the Nationill 
Cholesterol Educiltion Progrilffi [56J, il diagnosis of metabol ic syndrome requires 
three or more of the following: Hypertension, cent rill ildiposity (wilist 
circumference)' BMl greilter thiln 27 kg/m!, low HDL cholesterol, 
hypertriglyceridemiil, impilired glucose tolerilnce. Mccting the definition for 
metabolic syndrome hilS consistently been ilssociated with il 50'7<, increase in the 
risk of colorectill cancer [57-60]. Additionally, m.1ny of the individu.1l 
detcrminilnts ilnd consequenct's of insulin resis tilnce ilre independently linked 
with colorectill Cilncer [61 -63J. For eXilmple, excess centrill.ldipose tissue is 
.1ssociated with increaSt!<! colorectal ca ncer risk via its .1dverse effects on insulin 
sensitivity, infbmmation, growth factors and s teroid hormones [64, 651. A recent 
meta-ilnalysis [66J of 31 studies found th,ll obesity (BM I ;;,3Okg/m1) hilS a direct 
and independent relationship with colorectal cancer. The pooled results suggest 
tha t compared to those with a BM I of less than 25kg/m1, obese individuals have 
.1n increased risk of colorectal cancer (RR, 1.19: 957n CI, 1.11 - 1.29). However, 
obesity appe.11"S to prescnt.1 greater risk in men (RR, 1.41; 95% ct, 1.30 - 1.54) 
than in women (RR, 1,08; 95% CI, 0,98 - 1.18). The reasons for this dispilrity aTe 
not fully understood, but it has been hypothesized that the prot(Xtive effect of 
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exogenous estrogen in postmenopauS<11 women may counterbalance the neg.:ltivc 
impact of cxcess adipose tissuc [65J. Altcrn,ltivcly, it has been suggested that 
body mass index is a poorer indicator of visceral adipose tisslll.~ in women 
relative to men [671. 
Physical inactivi ty is a lso a risk factor that is independent of obesity and other 
potential confounding factors. The resuits of a meta-analysis [68[ of .to case-
control and cohort studies suggested that a significant reduction in colorectal 
cancer risk could be achievl..-d with physical activity. Furthermore, any .:Imount of 
activity appears to be beneficial [69] illld the risk decreaSt.'S with increasing 
activity 170J. 
Hypertcnsion, elevated blood glucose, hyperinsulinemia and type 2 diabetes 
.:Ire metabol ic abnormalities associated with insulin resistance syndrome thilt are 
also independently associated with colorectal cancer [6 11. Type 2 di'lbetes is a 
conSl..'<]uence of long-term insulin resistance ,md is associated with a signific,lnt 
increa'-C in the risk of developing colorectal cancer. The findings of a recent 
meta-analys is [63J suggest that type 2 diabetes increases the risk of colorl..'Ctal 
ca ncer by thirty percent (95'%, CI, 20% - 40'70). 
The underlying mechanisms linking insulin rl..'Sist,lnce syndrome wi th 
colorectal cancer are not fully understood, but the available evidence suggests 
that hypt'rinsulinemia is the likeliest cause. This is supported by animal modl..'l 
and il! vitro studies, which h,1\'e demonstrated that insulin strongly promotes 
carcinogenesis via its efk'Cts on cellular proliferiltion and i1poptosis [61, 65J. 
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212.3SIIIOkillg 
Epidemiological evidence 171-74 ] utilizing cross-sectional, case-control and 
prospective cohort study designs strongly indicates that smoking is a significant 
colorectill cancer risk filctor. Por example, two recen t cross-sectionill s tudies [72, 
73] found wrrent smokers to be significantly more likely to develop advanced 
neoplasia than non-smokers. A case-control study 17l] found that 40 year+ 
smokers were 1.92 (957<", Ci, 1.13 - 3.28) times more likely to develop colorectal 
cancer than non-smokers. A prosp!;'ctive cohort s tlldy [74], which follow!;'d 
25,279 middle-ilged }ilpillWS<.' men for 7 yeilTs, found thilt pilSt smokers (]{J{, 1.73; 
95 /-;-, Ci I.04 - 2.87) ilnd current smokers (RR, 1.47; 95'f" Ci 0.93 - 2.34) were 
significantly more likdy to develop colorectal cancer when compar!;'d to never 
smokers. Additionally, it WilS reported that a greater number of cigilfcttes 
smoked pef day and an eilr lier ilge of smoking onS-t' t incrCilS(" the risk of 
colorectillcancer. 
The mechanism by which smoking increases the risk of colorectal cancer is 
not entirely clear. Tobacco smoke contains likely carcinogens including 
polycyclic hydroca rbons, aromatic amines and benzene [75[. More recently, 
smoking has ~n linked to incr!;'ilsed DNA methyltransferase activity, 
suggesting thilt it mily promote cil rcinogenesis viil epigen!;'tic mechanism s [76, 
771. Th!;' consistency of the evidence slIgg!;'sts tha t smoking increases colorectal 
cancer risk. However, several qll!;'stions remain lInanswer!;'d, such as: how does 
smoking modify color!;'ctill Cilncer risk in certain subgroups that have a geneti c 
p redisposition? 
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2.3 CRC Prcveutioll 
A number of therilpit.'S are thought to function as colort.octal cancer 
chemoprevcl1tiltivl'S agents. The list includes: non-steroidal anti-inflammatory 
drugs (NSAIDs), COX-2 inhibitors, dietary supplements, hormone replacement 
therilpy (HRT) and statins. 
The chemoprcvenliltivl' attribules of ilspirin and other non-steroidal ilnti-
inflilmmiltory drugs (NSA IDs) hil\'e received Ihe mosl scrutiny ilnd ,1r(' the most 
promising. Aspirin ilnd NSAIDs function to inhibit inflammatory pilthways thai 
plily an important role in coloreclal carcinogenesis [78 [. The US Preventive 
Services Task force (USPSTF) recently published two systematic reviews 179, 801 
examining the benefits and harms of ilspirin and non-aspirin NSA IDs for the 
pTl'vcntion of colorectill neopla~ i il. Their ilnillysis found thillthe regular use of 
ilspirin reduced the incidence of adenomas in Refs (HR, 0.82; 95% C1 0.7 - 0.95), 
cohort studies (H R, 0.72; 95% C1 0.61 - 0.85) and in case-control studies (HR, 0.87; 
95% C I, 0.77 - 0.98). Furthermore, the efficacy of aspirin was increased when 
used at high doses and when used for periods longer than ten years. Similarly, 
the use of non-aspirin NSAIDs was associilled with a reducl-d risk of developing 
colorectal cancer in cohort (H R, 0.61; 95% C1 0.48 - 0.77) and c.1sc-control studies 
(l-lR, 0.70; 957<, C1 0.63 - 0.78). The CilVCilt is thilt the use of high dose ilspirin ilnd 
non-ilspirin NSAIDs were illso found to be ilssociated with dose-related increilscs 
in the incidence of g,lslrointesti l1 il[ compliciltions. Bilsed on the aVil ililble 
evidence, the USPSTF's ft."'Commendiltion was 10 not supporl the rl'gu[ilf usc of 
ilspirin or NSAJDs for the prevention of colorectal Cilncer, ilrguing Ihilt Ihe 
benefits do not ouhveigh the potential harms 179, 80]. 
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It has been hypothesized that folate supplementation may reduce the risk of 
colorectal cancer. However, this has bt!t!n refuted by a recent study [tnt in which 
1,021 patients with a hi story of colorectal adenomas wefe randomized to receive 
either 1 mg folic acid per day or placebo, ,md separately randomized to receive 
low-dose aspirin, high-dose aspirin, or placebo. At the end of the follow-up 
period, those receiving folic acid were more likely to have three or more 
adenomas. 
Calcium supplementation has also been linked with a reduced ri sk of 
coloredal cancer. However, in a pooled analysis oflO cohort studies [82], 
patients in the highest quartile of total calcium intake were less likely to develop 
colorectal cancer (Pooled HR, 0.78; 95% CI 0.69 - 0.88) when compared to the 
lowest quartile. However, results from the Women's Health Initiative trial [S3], a 
randomized double-blind placebo controlled trial, found no differl'tlce in the 
incidence of colorectal cancer betwet;'n those who did or did not receive 
combined calcium-vitamin D supplementation (HR, t .08; 95% CI 0.86 - t .34) 
From the same study cohort [84[ the usc of hormone replacement therapy in 
postmenopausal women was observed to significantly reduce the risk of 
colorectal cancer (J-IR, 0.63; 95% CJ 0.43 - 0.92), which was confirmed in another 
case-con trol study [85]. However, hormone replacement therapy was 
subsequently linked [84] to increased breast cancer and cardiovascular disease 
risk, and therefore could not be recommended as a chemopreventative agent. 
The risk of colorectal cancer was reduced by 47% in tho* who used statins 
for g reater than 5 years, according to one case-control study [86]. However, 
subsequent studies [S7, SSI did not confirm those initial findings and a recent 
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meta-anillysis [89 [ found no benefit of stiltins in either rilndomized controlled or 
cohort studi t!s 
Al though some thernpies nppear to red uce the risk of eRe, they are 
unfortunillely eit her associilled with considerable toxicit ies or hilve fai led to 
demonstra te effectiveness in Rcrs. Thus, no therapy is currently recommended 
ns a chemopreventa tive agent. The discovery of chemopreventative agents is 
chnlIenging and is compIicnted by the heterogenous e tio logy of colorectal cancer, 
thc long latent period of colo recta! carcinogencsis and potential toxicities. 
However, despite these challenges it is encouraging that the development of 
precancerous lesions ilnd ildenocarcinoma ilppears to be susceptible to 
modification by chemopreven tntive agents. 
2.4 Molecular Plltlrways 0IColorec/al Carcillogcllt'sis 
Approximately 30,%, of human genes encode for proteins that function to 
repai r ilnd maintain the genome [90). The integrity of the humiln genome is 
critica l for human heal th and dysfunction of these proteins often has severe 
health consequences. For example, inactivating mutations in genes that perform 
DNA mismatch rep.lir (Lynch syndrome), b.lsc-excision repair (MUTYH-
associated polyposis), double-strand break repair (BRCAl and BRCAl), and 
nuc1l;'otide excision repair (Xeroderma pigmentosum) result in severe cancer 
predisposition. Colo rect .. 1 carcinogenesis progresses via a sequential 
accumulation of genetic and epigenetic a ltcf<ltions and m<lny of these <lltcrations 
<lffed genes thilt fu nction to milintilin tht! int t!grity of the geno me. Thl;'se 
obscrviltions have led to the hypothesis that genomic inst .. bi lity pl<lys a ("fucial 
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role in the etiology of colorectal carcinogenesis. Unfortunately, the ~pecific 
mechanisms causing genomic instability are unclear, but it is associated wi th the 
genome incurr ing point m utations, sma ll dele tions and insertions, and gross 
chromosomal alteration~. Over the pa~t decade it has become evident that 
genomic instability can be achieved by at least three broadly dist inct molecll l.1r 
pa t hway~ of ciHcinogene~i~ [4[. lhl'~e pilthWily~ Me recognized as the: 
chromosomal-instability (ClN), microsatcllite-instability (MSI) and serrated 
pathways. Al though they are not entirely mutu.111y exclusive, these p<lthw.1Ys 
arc relatively uniq ue from both a molecula r and cli nical perspective. The 
mok'Cular p.1thology of colorectal carcinogene~i~ i~ li kely far more complex than 
thrl'C molecular pathways, but our current understanding of these pathways 
prov ides a framework from which to direct fu rther research. These three 
pathways of carcinogenesis, along with thei r associa ted syndromes, are de;cribt.-d 
in further detail lx-low 
2.4.1 Chrom()s()mllll'!~labilil.'l (ON) Pat/willy 
The most common pathw.1Y through which colorectai cancer occu rs is the 
ch romosomal-in~tJbili ty (ClN) pathway. The O N pJlhway is chJrJctl' rized by 
aneuploidy, numerous base substitution~, deletions, insertions, chromosomal 
rearrangement~ and copy number changes [91 [ and are commonly associated 
with mutJt ions affecting Al'e, KRAS, p53, l'IK3CA, and SMAD [92 [. The 
IlrimomlltOllS polyposis coli (APe) gene, w hich i~ pilrt of the Wnt ~ignal ing pat hwilY, 
i~ thought to playa princip.ll role in the ON pilthway of colorectal 
carcinogenesis for several reasons: i) germline m utations of APC ll;'ad to sevt:'re 
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polyposis synd romes (e.g. FAP) [93[; ii) somatic APe mutations are frequentl y 
observed in sporad ic colorecta l tumours (70%); and iii ) alteril tions of APC (an be 
fo und in the earl iest eRe p re(ursor lesions and often precede all other molecular 
alterations [94,93[. 
The APe gene product has.1 host of cellu la r functions, one of which is the 
regul,lIion of the Wnt signaling pathw,lY. p-ca tenin activates the Wnt signaling 
pathway by bind ing to transcription factors that initiate tr,l11scription of gmes 
that promote prolife rilt ion, such ilsMYC and CYCL/N D1. The APC protein 
normally fun ctions to negil tively regulate the Wnt signaling pathway by binding 
p-ca tenin and mediating its degradation. However, mutations of APC often lead 
to tru n(,ltro proteins that have impaired function, thereby .1l1owing p-catenin to 
translocate to the nucleus nnd cn using over-activ<llion of the Wnt signaling 
p<lthway. 
Components of the mitogen-activated protein kinnsc (MAPK) signnling 
pathway <lfl' also often perturbed in CIN tumours. KRAS is a component of the 
MAPK s ignaling pathway and it is normally deactivated by GTP hydrolysis, but 
specific mutations a llow KRAS to remain in an activated state. Activation of the 
MArK signaling pathway promotes incrt'ased cellular proliferat ion and survivnl. 
Mutations of KRAS Me found in carly adenomas, but are more fre'luently 
observed in adv.lI1ced adenomas (50',1,, ) and with adenomas larger thnn I cm in 
diameter (38%) [961, which suggests that KRAS mu tillionsoccur ea rly in 
tumourigenesis and promote adenoma g rowth, but arc not neCeSS<lfY fo r 
rl1nlign<lllt transformation [97[. 
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The p53 gene is a tumour suppressor gelle that is involvl-d in maintaining 
genomic stability via control of the cell cycle. In response to genotoxic stress, p53 
lip-regulates a number of genes that directly block the 0..,11 cycle and initiall' 
'lpoptosis. Inactivating mutations of li53 are commonly observed in tumours 
<Hising from the CiN pathway, and they confer an advantage to the cell by 
allowing it to evade apoptosis. 
Although the above-described genes are frequently mutated in CIN 
tumours, they do not appear to be the primary cause of CIN. The mechanisms 
that cause CIN are largely unknown, bu t perturbations in genes that regulate the 
cell cycle, mitotic spindle checkpoint, centrosome number and telomeres <He 
thought to be likely candidates. Aneuploid tumou rs often display additionally 
abnormalities duri ng mitosb - such as abnormal centrosome number, multipolar 
spind les and lagging chromosomes - which strongly implicate genes that regul,lte 
the mitotic spindle checkpoint 198). For exampk mutations in MAD and BUB 
have been linked to CIN colorectal tumours because mutations in theS(' genes 
often caliS<' abnormalities during mitosis 199). Abnormal centrosome num ber 
and function have also been implicated in CiN tumours. Several stud ies are in 
support of this, fo r example a locus at 2Uq 13 was observed to be frequently 
amplified in hUllhlll epithelial tumours [1001 and lOIter stud ies identified the 
5TKl5 gene at that locus. Subsequently, 5TKl5 amplification was commonly 
ob..;erved in breast [\OIl and colon cancer cell lines 1 \021. Ovt'r-expression of 
STKJ.'J has been identified as a potential cause of mitotic spindle assembly 
abnormalities [981. In addi tion to 5TK15, a number of DNA checkpoint gel1es arc 
also linked to Ci N, which include mutations and amplifications of ATM, ATR, 
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BRCA1, BRCA2, PLKl and CDC4. However, it remilins unclear whether these 
al terations are ca usMive or just permissive of C1N. 
1.4.1.1 Familial Adelloma/UIIS Pol)'fJOsis (FIW j 
Familial adenomatous polyposis (FAP) is an autosoma l dominilnt 
hereditary polyposis syndrome causl.,d by mutations of the Illit'!lIJlIIlltOIl5 poi.'llltJsis 
wli (APC) gene. The genetic etiology of FAP was initially located to a region nt 
5q21 -22 [\O3[ nnd the APC gene \\',lS subsequently identified in clinicnlly 
identified families 11041. The majority of mutiltions affecting APC occur in exon 
15 and commonly result in trunCilted proteins. The APC protein normill1y binds 
~~-cn tenin and mediiltes its degrildiltion, but the tnillciltcd Al'e protein poorly 
binds ~-ciltenin. This enilbles ~-ciltenill to trilllsiocilte to the nucleus ilnd cause 
over-expression of the Wnt signaling pathway. 
In classical FAP, germline mutations of APC Me neilrly 100% pent'lrant 
[105[, but FAl' accounts for less than 1% of all colorectal cancer. P,ltients 
typically present with hundreds to thousands of adenoma tous polyps of the 
bowel ill ,m early age and develop colon cnncer by the four th decnde of life 11061. 
For this reason, p,ltients undergo prophylactic surgery to remove the bowel. FAP 
is also ilssociated with an increased risk of peri-ampullary adenoma and 
c,lrcinoma, medulloblastoma, papillary cMcinoma of the thyroid, 
hepatoblastoma, carcinoma of the stomnch and congenital hypertrophy of r .. tinal 
pigmented epithelium [1071 
Germline mutations of APC arc also the etiological basis for altenu,l ted 
familial ildenomatous polyposis (AFA!,). Compared to FA!', AFA!' is 
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characterized by fewer polyps and a tendency for proximal colonic ,1denomas 
2.4.2 MicroSllldlile-II1Slabilily (MSI) (111111/('11.11 
Microsatellites are short repeating DNA sequences that arc located 
throughout the genome. They ,Hl' susceptible to errors during DNA replication, 
particul,uly if the human DNA mismatch repai r (MMR) system is impaired. The 
1l1icrosatel1ite-instilbi lity phenotype is defined by il varbtion in the length of 
sequences in DNA derived from the tumour. The phenomenon was initially 
observed in the malignant colon tissue of cancer syndrome patients [109, 110] 
and subsequently linked to Lynch syndrome. However, 10% - [510 of non-
Lynch syndrome colorect,11 patients (i.e. sporadic colorcdal C.lncer patients) also 
have tumou rs that are microsatellite-unstable, suggesting that the MSI p,lthwilY 
has an alternative etiology. Further investig,ltion led to the discovery thilt the 
MSI pathway in 'sporadic' colorectill cancer tumours WilS the result of ilberrant 
epigenetic inactivation of MLl-11 by promoter methyliltion [[ III. This 
phenomenon is s trongly associated with the serr,lted p,lthway, which will be 
discussed separately. 
The MSI pathway is characterized by a distinct clinicopilthological profile. 
MSI tumours ilre often locatt.'<i in the proximal colon, and tend to be mucinous 
ilnd poorly differentialt.>d [112, 1131. Patients who have a MSI tumour ,1re 
associilted with a better prognOSiS than patients who have a microsatellite-slab!e 
tumour 11[41. 
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2.4JII.YII('h,I,),lIdrOIll(' 
Lynch syndrome is the most prevalent known inherited colorectal cancer 
syndrome and is attributable for 2';:, - 4'(" of the colorectal cancer burden 11151. 
Lynch synd rome cauSt;!d by inactivating mutations o f MLHI, M5H2. M51/6 and 
1',\1152. The correspondi ng proteins function to perform DNA mismatch repair 
and dysfunction of this system significantly elevates the risk of developing early-
,1ge tumours of the colorectal, endometrium, ovary, s tomach, small bowel, 
hepatobiliary tract, pancreas, ureter, renal pl'lvis, brain and sk in 11161 
2.4.2.1.1 His/ory 
An American pathologbt, Aldred Warthin, firs t documented the clinical 
manifestations of Lynch syndrome in a [913 publication, which reported his 
findings of a cancer predisposition family "Family G". Decades klte r, Henry 
Lynch extensively reSl'<Hched the family his tory of a fam ily known as Family N, 
which displayed many of the features of what is noll' known to be Lynch 
syndrome. At the time it was recognized that Family N members did not present 
with multiple polyps, which were known to be associated with FAP - the only 
known hereditary c,ltlcer syndrome at the time. Lynch continued his rese<lrch 
efforts by updating the work founded by Warthins' Family G and by 
collaborating with others who h<ld identified <l similar canCt!r family (Family M) 
111 7,1 181. In 1971 , Lynch d II/ reported on the clinical features th<lt identified 
"cancer family syndrome" which included, increased adcnocarcinomil of the 
colon and endometrium, multiple primary malignancies, early ilgC onsd and 
autosomal dominant inheritance 1119J. II WilS not unlil the 1990's thilt the 
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etiology of Lynch syndrome W;;lS discovered [[20, 1211. During this ~riod, The 
lnternatioml Collaborative Group on HefeditMY Non-Polyposis Colorect;;ll 
C;;lncer (ICG-HNPCC) was formed, which collilborilted on rese;;lrch efforts, 
promoted ;;lW;;lfeness and developed clinic;;ll criteria to identify Lynch syndrome 
f,lmilies [122J. As a result of the t~hnologica[ adv;;lncements m;;lde in molecu[ar 
genetics, a vast amount of knowledge has been acquired regarding hereditary 
co[orectil[ C;;lnCer, which will be di scussed below. 
2.4.2.1 .2 Eli%SY 
The human DNA MMR system functions specifically to repair s ingle-base 
mismatch errors and insertion-deletion loops that occur during replication and 
recombin;;ltion. DNA MMR function wils originally identified in E.coli, and 
homologues of the E.coli MMR genes have OC't'n found in ye.lst and nl;;lmmil[S 
["[23J. The link between mism;;ltch rep;;lir function and Lynch syndrome was fir st 
identified in 1993 when a susceptibili ty locus was mapped and assigned to 
chromosome 2p by link;;lge ;;In;;l[ysis [120]. A human homologue of the MSI12 
gene in yeast [1241 was cloned I [25] and WilS subsequently linked to Lynch 
syndromt! based on germlinc mutations in several families with severe cancer 
predisposition [126J. Likewise, M I.Hl WilS cloned by its yeast homologue [127, 
128] and germline mutations wefe linked to Lynch syndrome in [994[1281. 
Later. mutations in two addition;;l[ genes implicated with humiln DNA MMR 
were found to cause Lynch syndronle - /'.-1.152 11 29], followed by MSH6 [ 130, 131]. 
The human DNA MMR system is comprised of numerous proteins that 
collectively function to perfo rm DNA mismatch rep.lir However, MLH [, MSH 2. 
MS116, and PMS2 arc critical for proper functioning of the MMR system. These 
proteins, along with others, form heterodimeric complexes that play sjX'cific rolcs 
identifying and repa iring DNA mismatch errors. The MutS comp lex, which 
couples MSH2 with MSH6 or MSI-I3, functions to identify m ism<ltch errors <lnd 
binds to DNA bYl'xchanging ADI' for ATP, The MutL complex invol ves MU-Il 
coupling w ith PMS2, PMS I, o r MLl-I3, which binds to MutS dimers that h<lve 
recognized DNA errors. The MutS-M utL complex subsequently acti v<ltes 
endol1uckast' ,lCtivi ty to repair mismatch errors. This model implies tha t some 
degree of red undancy ex is ts, which is also observed ciinic<llly. Since MLHI <lnd 
MSl-I2 Me critical for proper mismatch repai r function, thl'Y <lccount for <l 
m<ljority of known MMR mutations. In this model MLI-Il can for m heterodimers 
with eit her MLH30r I'MSI and therefore a mutation of MUD or PMSl appears 
to have littk or no phenotypic effect [132] 
Germline mut<ltions in MMR genes can result in proteins with loss of 
inter<lction domains o r with changes in conformation that ultimately impair their 
ability to inter<lct <l nd function. Mutation carriers have one nOTmill allele thilt is 
thought to be sufficient for MMR function, and tumourigenesis occurs only ilfter 
in<lctivil tion of the wild-type allele, which mn occur by ei ther loss of 
heterozygosity, somatic point mutation or promoter methyl.ltion. Imp<lircd 
MMR function undermines genomic integrity by significmltly increasing the 
mut<ltion rilte and lead5 to numerous DNA errors occurring throughout the 
genomc in a non-rilndom fashion. ~gments of the genome tha t contain 
micros<ltellite repe<l t st.'<j uenct.'S <lre most susceptible to mismatch errors. 
ConSClluel1tly, MMI~-ddiciency often le.lds to inacti va tion of many tumour 
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suppressor genes that conlain microsatellite-likc repeats, such as TCFB1<21133i, 
TCFIII< [ 134[, PTEN [ 135], as wl'll as gl'nes involved in Wnt signaling [1361 and 
,lpoplotic pathways [1371. The TCFBI<2 gene product controls a number of 
signilling pathways involved in growth inhibition ilnd cellular death. 
Ill<lctiviliing mutiltiolls of TCFBR.2 ilre commonly observed and cause the 
receplor 10 be insensitive 10 the growth inhibitory effects ofTGF-Bl. 
Furthermore, activating mutations of B-catenin are frequent and cause over-
expression of the Wnt Signaling pathway by up-regulating the transcript ion 
f,lCtOrs MYC and CYCLIN Dl. Inactivating mutations of BAX, il gme thilt is 
critical fo r cell death, are common and enable tumour cells to eVilde apoptosis. 
[n 1994 the illlerniltiollill Coltilboriltive Group on Hereditary Non-Polypo~is 
Colorectal C.lllcer (1CG- HNFCC) t.'Stilblished a diltilbilse of MMR mut.1lions. In 
2003, the lCG-HNPCC ilnd the Leeds Castle Polyposis Group (LCPG) merged to 
form INSIG HT (1nternational5ocicty for Gastrointestinall-lereditary Tumours). 
At thilt time, 448 pilthogenic mutations were documented in 748 affected fami lies 
from around the globe. To dale, germline mutiltiolls in MUll, MSf-I2, MSH6 and 
PMS2 are definitively associated with Lynch syndrome. However, mut<ltions of 
severil l other MM R genes such ilS, MLH3, I'MSl ilnd MSH3 ilre less likl'ly to be 
pilthogenic, but their involvement is not yet fully unders tood [1381. Mutntions in 
MLJI1 <lnd MSIl2 ,lCCotmt for the miljority of Lynch syndrome cages 
(approximately 90%), and mutalions of MSI-I6 and I'MS2 ilccount fo r the 
remainder. Most mutations are frameshift and nonsense mutiltions that leild to 
trullc,lted proteins, but missense mu tations are also reported in more than one-
third of all mu t<ltions involving MUll and MS/-/6 [138[ 
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Founder mutations arc pathogenic mutations that account for a large fraction 
of the total disease burden in a specific population. Founder mutations occur by 
a single mutation carrier introducing a novel mutation into ,) population, which 
over a period of generations may be responsible for a disproportionate amount of 
disease. For example, a specific MSI 12 mutation (c.942+3A -T) is eslim,lttx[ to 
;;!ccount for 5% - 10% of all Lynch synd rome patients worldwide 11391. Certain 
features of a population increase the prob;;!bility of a founder mutation 
flourishing, such as: isolation, rapid popul;;!tion growth and chimce [35[. Two 
founder mutiltions of MLHI have been identified in the Finnish population 1140, 
1411 and a si ngleMLl-Il mutiltion ;;!ffects the Swiss population [142]. MSH2 
founder mutiltions hilve been identified in North Americ,11l1143j, Ashkenilzi Jew 
[144] and Newfoundland populiltions 1145] . A Newfoundland filmily (Filmily C) 
was integral to the originallinkilge study that identified the susceptibility locus 
on 2p [120] . This mutiltion was subsequently identified in 12 independently 
ascertilined Newfoundlilnd filmilies, and was suggestive of il founder mUiiltion 
by il common hilplotype of markers [145] 
2.4.2.1.3 OiagJlosisaJld "(CStiIlS 
rlw ICG-HNI'CC first t.'S t;;!bli shed clinical criteriil to identify Lynch 
syndrome patients in 1991 [122]. Fulfilling the Amsterdam! criteria (AC-i) 
requires [122] that: a) at least three relatives should hilve his tologically verified 
coloredill Cilncer and one of them should be a first-degree relative of the other 
two; b) two successive generilt ions should be il ffected; c) one of the affected must 
be diagnosed before fifty ye,lrsof age, ilnd d) FA!' must be excluded. In 1998, the 
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Amsterdilm II criteria (AC- II) were introduced 11161. which exp.1nded the 
origin.ll AC-I criteri.1 to include cilncers of the endometrium, ureter, rl'nill pelvis 
and small bowel. The Amskrdilm criteria were critici zed for lacking clinicill 
sensiti vity and subsequently, the Bt,thl'Sda gu idelines 11461. followed by the 
revised Bethesd.1 guidelines in 2004 [ [47], were cre.1ted in order to identify 
p,ltients who should undergo MSI ilnd or IHC test ing 
A workshop fo r the Europe.1ll gu idelines for the clinicill nl.1nagt'ment of 
Lynch sy ndrome in 2007 .1ssessed the performance of the Amsterd.1m .1nd 
revised Bethesda criteria. It dcll'rmined that the sensitivity of the Amstcrdilnl 
and Bethl'Sda criteria for the dl'tect ion of mutiltion ca rriers was 4070 .1nd 90%, 
rl's]X'<tively 11481. The positive predictive val ue of the Amsterd.1m ilnd revised 
Bethesda criteria is approximiltely SO% and 10'", - 20,}::" rl'Spectivcly [149J. The 
workshop concluded thilt the revised Bethesda criteria wefe appropriilte for the 
selection of piltients whose tumours should und ergo moleculilr h:.'Sting for 
rnicros.1tellite-instilbility, considering the high-cost associil ted with illlt'rn.1tivcly 
tes ti ng illl p.1tient tumours [1481. 
Micros.ltellite-instability testing in volves comparing miltched normal and 
nl.1lignant tissue by using a panel of 5 to 10 specific microsa tcllite milrkcrs. 
V.1Tious thresholds fo r instability arc U5(.'(\, but genCTillly micros,ltellite instability 
(MSI-H) is determined if greater than 30% of markers demonstrate ins tability; 
MSI-Low if 10 - 30% arc ins table; and MSS if < 10';:, of markers arc instable [I SOJ. 
Approxim.1tely 90% of colorectal tumou rs that arise from Lynch sy ndrome 
exhibit MSI [1 2! J. Howt'vcf, MSJ is .1lso observed in approxim.1tely 15,):, of 
spofildic colorect.11 tumou rs as.1 result of epigenetic s ilencing of MLlf1 [II J J. As 
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a result, th~ specificity of MSI t\:!Sting for the detection of MMR mutation carriers 
is not ide,ll, but MSI testing is a reliable, sensitive and clinica lly useful test fo r 
identifying potential Lynch syndrome patients. Patients with a MSI-H tumour 
are recommended to undergo immunohistochemistry testing (tHC) testing and 
or screening for known germline mutations. 
2.4.2.1 .4 Lyllc/l SYlldr0l11l' Pm/ie/iOlt Algorithllls 
A diagnosis of Lynch syndrom~ is seldom straightforward and it often 
involvt.-s a combination of personal and family history information, as well as 
molecular diagnostics. Th~ most ~ffectiv~ and cost-~fficient strntegy is still 
debate<..i ,lnd several groups have developed MMI{-mutation prt.-diction 
algorithms in an effort to improve diagnostic efficiency. TheS(' prt.-didion models 
include the Lieden model/149], PREMM '.l I15 1], MMRprcdict l 1521 and MMRpro 
1153J. The various prediction models typically utilize personal history and filmily 
history information to estimatt;' the likelihood of being il MMR mutation cilrrieT. 
In villidiltion cohorts the PREMM I.1< MMRpredict and MMRpro prediction 
models hilv~ reported area under th~ curve (AUC) valut.'S ofO.SO (95% Cl, 0.76-
0.84),0.82 (95% Cl, 0.72 - 0.91) and 0.83 (95% G, 0.78 - 0.88), respectively. 
Jnter~stingly, despite utili zing different information and having different 
algorithms, the three models have reported si milar AUC valut.'S in validation 
cohorts 
The clinical utility of theS(' models for use in th~ g~nerill population has been 
questioned, particuiilrly sinn' these models were devdopt.-d and valida l~d lI si ng 
high-risk piltient cohorts. Two studies 1154, 155/ hilV~ independently ,lssessed 
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the clinical utility of these pn .. odiction models. The first study [154] evaluated 
these models using a cohort of 72 rl'fl'rred high-risk patients and reported that 
the PREMM, MMRpro, MMRpredict and Lieden models, but not the Myraid 
gent'lics modcl, performed better than the Amsterd,lnl II criteri.l. The reported 
AUC valul'S were 0.75 (95% CI, 0.64 - 0.87), 0.86 (95% CI, 0.76 - 0.96), 0.90 (95% 
CI, 0.82 - 0.97), 0.90 (95% CI, 0.81 - 0.98) and 0.93 (95% CI, 0.86 - 0.99), for the 
MyriJd, MMRpredict, Liedell, MMRpro Jnd PREMM u models, respectively. The 
authors concluded thJt the models performed welL However, the s tudy cohort 
was a high-risk group of referred pJtitmts. A more JppropriJte study by Green <'f 
111[155] eVJluJted the performJncc of these models using a lJrge cohort of 
popuIJtion-based pJlients. Gn..--cn filii reported thJt the prl'dicJlion Jlgorithms 
performed reasonJbly well (AVe values ranged from 0.9 ] - 0.%) Jnd 
outperformed the revised BethesdJ criteria. However, they tended to 
overestimJte the probability of low-risk pa tients having J MMR mutation. After 
correcting for family size, the best performing model WJS MMRpred ict. which 
Jchicved a scnsitivity of 94% (95% Cl, 73 - 99'70 ) Jnd a specificity of9] 'J" (95% CI, 
88 - 93% ). 
1.4.2.1.5 Cilllca Risk 
Lynch syndrome pJtients hJVC a subs tJntiJlly increast.od liability to d evelop 
colorl'ctal Jnd extrJcolonic mJlignJncies. Quantifying the C,lncer risk associated 
with Lynch syndrome is an important fJed of providing cvidctlCt'-bJst.>d health 
care, as accurate estimates of cancer risk C'n.lbles s trategil'S to bl.' implemcntt.>d 
th.lt reduce ca ncer-related mortality. However, obtJ ining accu rate and precise 
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estimiltes of Cilncer risk Ciln be chilllenging since the findings CJn be severely 
biJscd by the design and analysis of such stud ies. For eXilmp!c, soon ilfter the 
etiological basis of Lynch syndrome WilS discovcfl'd, severill iluthors [156- 159[ 
reported erroneously high lifetime l'Stimiltl'S for developing colorectal CJncer (as 
high as 82% ), IJrge1y because of using severely ilffected and clinic.llly ilscl'rtained 
familil's. SubSC<Juent studies [160-1621 utilized more appropriate study designs, 
patient cohorts ilnd statistic.ll methods to minimize the potential for bias, Jnd 
these s tudies have foun d lower estimiltes of c.lncer risk. For eXilmple, a study 
[1631 of MUll and MSH2 mutation carriers, which used il populi1tion-based 
cohort .ls opposed to clinic.llly aSCl.'rtilined filnlilies and incorporated both 
affected and unaffected mutation-positive family members, found illilter age of 
colorect.11 cancer onset Jnd a reduced penetr.mcc (69% in men .lnd 52% in 
women) compJred 10 eMlier studies. That being Solid, the findings of a rl'("ent 
study! 164! has estimilted thilt the lifetime colorecta! CJncer risk for men 
(cumulative risk, 66.1 %; 95'1.,0,59.5% - 76.2',1,, ) and women (cumll!Jtive risk, 
42.7'}1, ; 95% 0, 36.6% - 52.8%) Lynch syndrome piltients to be quik high. 
Lynch syndrome piltients ilre JI50 J t increased risk for developing 
extrilcolonic lTIillignJncies of the stomach, smJII bowcl, renal pelvis, ureter, 
OVJries, b iliary tract and brJin. Results Of.1 large study! 165[ of MUll ilnd MSH2 
mutation CMriers indicJted that the greiltest extr.lcolonic risk were Cilncers 
ilffecting the urological tract (cumulative incidence, 8.4%; 95'1., 0, 6.6% - 10.8',1,, ). 
The lifetime risk of ovarian (cumulJtive incidence, 6.7'1.,; 95% CI, 5.4% - 9.1 % >-
gilstric (cumlililtive incidence, 5.8%; 95% CI, 4.4% - 7.7%), smJII bowel 
(cumlllJtive incidence, 4.3%; 95% 0, 3.1 % - 5.9%), br.lin (cumlilativl' incidence, 
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2.1 %; 95% CI, 1.5% - 2.9';;,), and biliary-pancreatic cancer (cumulative incidence, 
4.1 %; 95'i"{, CI, 2.8% - 5.9%) was also rcported. The authors sllggesk'd that canCl'rs 
of the urologic tr,lct and ovaries occur frequently eno\.lgh in some Lynch 
syndrome fJmilies to justify CJncer screening. 
rhere is <llso evit.ltmce for mutation-specific differences in cancer risk For 
example, a study [164] thilt l'xillnined the incidence of C<lncer in 147 kindred 
affected by MLH1, MSH2 and MSlI6 mutations discovered that male MLHI 
mutation Cilrriers (RR, 342; 95% CI, 264 - 442) were at significantly greater risk for 
developing colorectal cancer than mille MSH2 mutation C<lfriers (RR, 78; 95% CI, 
57 - t07). Fl;'m<lll;' MLHl cJrriers were a lso at greater risk of eRC (RR, 76; 95% Cl, 
58 - 103) than female MSH2 carriers (RR, 46; 95% C1, 33 - 65), but this result W<lS 
not s t<ltistically significa nt. The risk of developing endometrial cancer in MLJ-/l 
(RR, 3t;95% CI, 20-SO), MSH2 (RR, 47; 95% CI, 35-64) and MS/16 (RR 18; 95% 
CI, 6 - 55) mutation carriers apfX'ars to be similar. There i~ also evidence ]165] to 
indicate that the incidence of urologiGl1 and ovarian cancers is significantly 
greater in MSH2 mutiltion Cilrriers than in MLH1 carriers. 
Furthermore, even within the S<lml;' MMR gene, different mutations appear to 
influence phenotype. For example, a study ]166] of thrl'"C New foundland 
fJmil ies, who had different mutations affecting MSI-I2, found significJnt 
differences between families for the risk of developing extracolonic malignancies 
However, the risk of developing colorectal cancer was compilrilbll;'. 
MSI16 mutiltions <lccount for only a minority (approximately 7'}:,) of known 
MMR gene mutations cilusing Lynch syndrome [ t3.';]. There is evidence [167-
170] to suggest that rela tive to MLHI ilnd MSH2 mutations, MSH6 mutations 
32 
h.we a lowt' r penetr,lIlcc, and that patients affectt.'<I by MSi-I6 mutations h,lVe a 
delayed age of onset of cancer, bu t a higher risk of developing endometrial 
cancer. A study [171 I of two Swedish founder MSH6 mutations found the 
lifetime risk for developing any Lynch syndrome-associated c.lncer to be 89% in 
women and 69% in men. Despite having a later-age onset of C.1ncer, the 
penetrance of MSH6 mutations appears to be high, suggesting that intensive 
counseling, management .1nd surveillance is necessary, but that eMly-age 
screening may not be as critical as with MLI f1 and MSH2 mutation c.lrriers. 
PMS2 mut.ltions account for.1 sm.111 proportion of Lynch syndrome patients, 
but they are likely underreported.1s molecular detection has proved difficult [91. 
As <l consequence, cancer risk in p.1tients affected by PMSl mutations is unc!e<lr. 
However, detection methods arc improving, which has enabled better 
<lscert.linment of patients with PMS2 mut<lt ions. The findings of a recent study 
11721. which <lscert.1ined .1 large cohort of colorectal cancer patients whose 
tumours stained negative for PMS2 on IHe , demonstr<lted th<lt PMS2 mutations 
are common in these patients (>60% were mut<ltion positive). The me<ln age of 
colorectal c.lncer onset in 55 mono.ll1e1ic PMSl mutation carriers was 50 yeMs, 
with <l r<lnge of 23 - 77 ye<lrs. lnteT6tingly, PMS2 mut.1tion carriers rarely h.1d a 
family history Ih.ll fulfilll'd the Amsterdam criteri.1 (9'}O ), however 655% satisfied 
the revised Bethesda criteria, while the fem<lining (255'}O ) fa iled to satisfy .1ny 
family history risk criteria. The fisk of colorcctal cancer W.1S comp<lf<lble in m<lles 
(lifdime risk, 20'70 ; (<lnge, I t'}O - 347<,) and females (lifetime risk, IS';;'; range, 6% -
35%). There W.1S some indication that c.uriers were at increased risk of 
extr<lcolonic tumours .1ssocialed with Lynch syndrome, but the finding was not 
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statistically s ignificant (P = 0.3). The lifetime risk of any Lynch syndrome-
associated malignancy in males (cumulative risk, 25%; range, 16% - 48''', ) ;md 
females (cumulativt' risk, 32'1<,; range, 21 % - 33%) is less than what has been 
typically reported for MLl-ll and MSH2 mutation carriers. 
The clinical heterogeneity th.1t is observed amongst Lynch syndrome p.ltients 
is suggestive of yd to be identified modifier genes. This h.1s oc't'n su pported by it 
study of Lynch syndrome piltients [173], which found that the risk of colorcctal 
C.1ncer \\'.1S decreased by vari.1nts loc.1ted at 8q24.3 .1nd t lq23. t. Further research 
in this field will illlow for even gre.lter prl'cision in estimiltes of cancer risk. 
The evidencl' suggests that males are at greilter risk for developing colorectill 
Cilncer thilll femilles, and that MLHI mut.1tion cilrriers are ilt greater risk th.1n 
MSI12 mutation c.uriers. However, the risk of endometrial c.1ncer is comparilble 
for MLHI ilnd MSII2 carriers. MSI-I2 mutiltion carriers hilve.l greilter proJX'llsity 
to devl'lop extr.1Colonic CilnCl'rs of the urologicill trilet ilnd OVilries. The 
phenotype in M5116 mutil tion carriers is v.lriilble, but the penl'lrilnce ilppeilrs to 
be high despite reports of l.1ter-.1ge onset of cancer. PMS2 mutiltion cMriers have 
reduced pendrance with a lift'\ime risk of 25% - 32% for .lny Lynch syndrome-
ilssociiltfli cancer. Larger studies ilre needed to refine estimiltes so thilt mutation, 
gender and tumour-specific screening protocols can be put into clinical prilctice 
with confidence. 
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1.4.1.1 .6 Acceieraled CarcillogCII{'sis 
The m.llignililt transfUfIll;l ti on of , \Jl ,1den0rl1d tnus polyp to in vasi ve 
LdrLi n(lrlla is estillla ted to t.lke 10 - 13 yeMs in average-risk popubtion - ddined 
as not h,lVing eitlwr a fam ily hi~t()ry of col,1recta l CJncer or a p redbposing 
condition. 111 pJtients with Lynch syndrome, the r,l(e of malign.lIl t 
tran ~forn1.!tion is acceler,lted and lllilY t,lke ,15 li tt le ,1S 2 - 3 ye,lrs [106, 1 12. 174[. 
However, Lynch syndrome pa tients who develop colorectill r ,m cer appear to 
have a better prognosis compJred to non-Lynch synd rome colof{'ctJ I c,lIlcer 
patients who have m k rosatell ite-stable tu mours [175, 176J 
2.4.2.1.7 CaI!cerSrret"lillglllllf Surveil/mice 
A 13-yeJr p rosp.xtiw study [1 77[ of Lynch synd rome PJ tien t ~ found tha t 
three-yea rly colonoscop ies resu lted in a 62% red uction in colorecla l ca ncer 
incidence, as well as a significanl red uction in colorecta l cJllcer-morta lity. A 
red uction in colorectal cancer-mort,1lity ,1S a resul t of screening ,md surveilL;lnct' 
has al so bt'en found by two other stud ies [178, 179[. A more rec('ll l study [180] 
by Stu ckless d II/eva luated the effectiveness of colonoscopic screening in 322 
MSI12 mutJtion Guriefs from Newfound lilnd and found that screen ing was 
associated with a decreased risk of colorectal cancer, a later age of onSt;' t and 
better surviva l. 
The benefits of screen ing and surveillance for red ucing CJncer incidl'nce ,1Ild 
mort,1Jily in Lynch syndrome pJ tienb a re dea rly evidt;'n t. The consensus 
regardi ng optiln<J 1 su rvei ll<Jnce for Lynch syndrome pa tients is two-yea rly 
colonoscopy ini tia led between the ages of 20 - 25 years and cont in ued to .1ge 80 
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YCilrs if the piltient is in good heill th. For families that are mutntion-negative but 
displily filmiliill cluste ring of colorectal Cilncer, colonoscopy is recommended 
ewry 3 - 5 ye.Hs, beginning:5 - 10 yea rs before the earl iest age of colorecta l 
cnncer diilgnosis in the immediilte family 11481 . Female Lynch synd rome piltients 
have a high lifetime risk of developing l'!ldometriill Cilncer (39.4';:,; 95~;;! Cl, 30.8% 
- 46.9%) [164) and for this reason nrc recommended to hnve annual endometri ill 
screening beginning ilt ilge 30 - 35 years, illthough the effec ti ven~s of this 
sCfccning has yet to be demonst rilted. Prophylilctic hysterl>ctomy mily illso be 
considered, ilS one study [lS I) demonstrated a significiHlt red uction in 
t;'ndometrial and ovarian cancer in Lynch syndrome patients who underwent 
hysterectomy compilred to those who did not. Similarly, despi te thnt the 
evidence for efficacy is minimal, it is recommended that those with a filmily 
history of cancer affecting the ureter, renal pelvis, stom.lch or small bowel seek 
ilppropriilte screening [91. 
2.4.3 Serra/t'd .I\,1("opll1~ia Pathway ofCarci'wg~'w~is 
It is evident that an illternative p.lthwa), of colorectill cMcinogenesb co-exists 
wi th the ClN and MS[ pilthw.1Ys of c.lrcinogcnesis. Recognized ilS tht;' Sl:'rril ted 
neoplasi.l p.lthway [ 182[, it is .lssociilll'd with scrrilted adenomiltous Pl"e('ursor 
lesions, which Me differentiated from conventionill ild('nomiltous polyps by 
rnokcu liH ilnd morphologicill feiltures. The serrilted pilt hwily mily be im pl icilted 
in 201<, of colorectill cancers and particulilrly with intcrvill Cilnccrs [183), i.e 
colo[ectal tumours arising within ,1 short period of colonic screening. The 
etiology of the serrilted pathway is unknown, but activat ing mutations of the 
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MArK p<lthway ilnd dy~function of gene promoter methybtion ,1ppeaTs to playa 
prominent role. Furthermore, ~u~ceptibility to develop colort'ctal cancer via the 
st'rr,lll'd pathway appears to be influenced by both genetic and environmental 
factors 1184, 1851. 
2.4.3. f Serrated Prec/II"sur LI'.\·iom 
In the bte 1980s investigiltors reported that a rare syndrome associated with 
the development of multiple colonic hyperplastic polyps, now recognized as 
hyperplastic polyposis syndrome (HI'S). was il~sociated with an elevated risk of 
developing colon.'Ctill ca ncer II86J. Further investigations revealed that colonic 
lesions occurring in patients who had HI'S were morphologically distinct from 
the innocuous hyperplastic polyp 11871. In 2005, a classification system for the 
heterogenolls group of lesions referred to as serrated polyps was proposed 1188], 
which recognized several different types of serrated polyps. The hyperplastic 
polyp is the most previllent type ilnd ilccolmts for 80% - 90% of <III serr<lted 
lesions. These polyps ilre typically small (i.e. less thiln 5nun in dimension), hil ve 
littk· m'llignilnt potentiill ,md ilre commonly found in the distill colon of the 
elderly. The defining morphological fe<lture of the hyperplastic polyp is the 
appearance of serration along the upper half of the crypt. The advanced serrated 
polyps include: traditionill seffilted <ldenomilS (TSAs), sessile serrated adenomas 
(SSAs) and mixed polyps (MI'). Unlike the hyperplilstic polyp, thesc lesions have 
considerable malignilnt potential, can be large (> !em) and are distributed 
throughout the entire colol1. Traditional serrated ildenomas are characterized by 
a hybrid of dysplasic (typical of an adenon1<ltous polyp) and serr,lted .uchitecture 
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[189J. TSAs tend to occur in the distal colon and are frequently associated with 
mutations of either BRAF or KRA5, as well as with mcthyliltion of thl' 0-6-
mcthylguillline DNA methylt ril nsferase (MGMT) gene. One study [190 [ 
ind icated that 15.9%, of illl polyps were serrated ildellomas, but estimi1les of their 
previllence rilngt'S considerably. The sessile serril ted ildenoma was first 
described in 1996 by Torlakovic l'f III [191 [ and these lesions are characterized by 
il rchitedural features such as, T or L-shaped crypts. Unlike hyperplilstic polyps 
where serriltion is limited to the upper hillf of the crypt, SSAs are defined by 
serrillion thilt extends to the bilse of crypts 
2.4Jl MO/I'ClIklr r'(,lIII1I"CS 
The serrated pathway of carcinogenesis is s trongly associilted with two 
molecular abnormalities: the epG island methy lator phenotype (ClMP) .1nd the 
50miltic V600£ BRAF mutation. The cause of these aberriltions is unclear, bu t it is 
s lispected thilt they Me impli cilted with the etiology of the serra ted pathway 
2.4.3.2.1 epG Island Me/hylator ['how/ype (C/MP) 
epG dinucleotides ,He dinucleotides locilted throughout the human 
genome. Certilin regions of the genome contilin higher frcquencies of epG 
dinucleotides and .1re known as CpG isl'lIld s. CpG islilnds MC locilted ilt the 5' 
region of approximiltely 50% of illl gcnes ilnd ilre typica lly in the un methylated 
stil te [1 92J. Epigenetic l1lethyliltion of epG islilnds can impair DNA transcription 
by eit her directly inhibit ing trilnscription filcto rs from binding to promoter 
regions, or by inducing changes in chrol1liltin structure. Epigenetic modification 
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of epG islands has numerous im portant f~mctions in hum .. n biology [193[, but in 
some circumstances the regulation of DNA methylation becomes deregulated 
and consequently pathogenic. As an example, aberrant DNA methylation 
promotes carcinogenesis by inilctivating tumour-suppressor genes [194-I99J 
Approximately 20'70 - 30',1" of colorectill tumours display extensive 
methylation of epG is lands and this phenomenon has been suggested to 
represent a dbtinct subtype of co lorectill Cilncer, te rmed epG islilnd methylil tor 
phenotype (ClMI') [194, I99J. The l'Iiology of elMp is unknown and whether 
this phenomenon signifies a d isti nct molecular subtype of colorect .. 1 cancer has 
bt.~n debilted [2001. However, ilccumuli11ing evidence suggests that e lMI' is il 
unique subtype of cancer that is strongly associated with the serrated path Wily of 
cilTcinogellt.'"S is. It has been demonstrated that aberrant DNA methylation is 
p,lthogenic, affects a lilrge number of known tumour suppressor genes and is 
ob""'rved in ilberrilnt crypt foci and early ildenomilS, whi ch suggests thilt ilberrilnt 
nll'thyl<ltion occurs ea rly in colorectal carcinogenesis [111,201 -203 [. 
TumoUTs displaying ClMP c .. n be categorized as high (ClMP-H) .. nd e lM I'-
Low (e lM!'-L) [204, 2051. ClMI'- H tumours display ex tensive mdhyl<ltion of 
epG islands and tend to be associated with microsatellite-inst .. bility (M51-H ), the 
somatic V600E BRAF mutation and sessile serrated adenomas. Conversely, 
e IMP-L tumours display a lower level of aberrant DNA methyla tion ,md are 
mo re strongly associ .. ted with the dist .. 1 colon, with lesions exhibiting low-level 
micros,ltellite-ins tabi li ty (M51-L) or micros,l tellite-stilbility, methylation of 0-6-
IlIdllylgllflllitll' lIIelllyltralisferast' (MCMT) and m utat ions of KRA S r,lther than 
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I1RAF 12061. Furthermore, the ClMP-L phenotype ilppe.lrS to bt· more st rongly 
ilssociated with traditionill scrrah;d adenomatous precursor les ions. 
2.4.3 .. 2.1 V600£ BRAF Mull/lio!! 
BRAF is a component of the Rils ! Raf ! MEK! MAPK signal transduction 
pathway, which plays an important ro le in ('{'Bula r growth, proliferation, ':lnd 
apoptos is 12071. The somiltic V600E BRAF mutation is il T-to-A trilnsvcrsion thilt 
results in the constitutive activation of BRAF. The mutJtion is frequent ly 
observed in mdilnomil ilnd cOIOrt.'Ctill Cilncer, ilnd is recogni zed ilS a prim.lry 
genetic event in cilrcinogenesis ilnd as h;"tving mild oncogenic effect 1208] 
Approximilte1y 10% - 18% of illl colorectill tumou rs ilret.'Stim.lted to hilve the 
mutiltion [209-211]. The mutiltion is strong ly .lssodil ted with ClMP and the MS[ 
phenotype [ [99,209-2 121. but it occurs rilTe1y with MS[ tumours ilrising from 
Lynch syndrome [2131. Furthermore, the mu tiltion is seldonl observed in 
adenomJS and hyperplastic polyps, but is commonly associilted with trilditionill 
serril tcd adenomasJnd sessile serrJted adenomas [214-21 71. Fo r example, 
JPproximil tely 30'70 of tTJditionJ[ serrated 'h.ienomas and 781<, - 90'1<, of sessile 
serrJted ildenomJs ilre reported 10 hil rbour the mutilt ion. Furthermore, the BRAF 
mut.ltion ilppcars to be associ.lted wit h femillt.'S, smoking and proximill tumour 
loc.l tion 12[4, 2[7, 218] ilnd V600£ tumours typical ly present with mucinous 
morphology, tumour-infiltrating lymphocytes Jnd tend to be poorly 
differentiiltcd 12191. 
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1.4.3.3 S{'J"/"(/(I'd P(/(hll"(/Y.'· ojC(/J"C"illogclI('sis 
Then~ is ilccunlulilting evidence for illtcrn<ltive p<llhways of c.lrcinogellesis 
existing within the seTTJted pathwJY. One pathwJY is characteri zt't.i by the 
strung JssuciJtion betwt.'en CIMf', V600E BRAF, micrusJtcllite- ill~ tability and the 
sessile S{'TTJted JdcnomJ !l99, 209, 211 , 212, 214-2 17, 220 ]. This pJthway is 
referred to .1S the sessile serrated adenoma (SSAj pJthway, or s imply, the 
scTTJted pathwJY. Sessile serrated adenomJs Jrise from the microvesicular 
hyperplJstic polyp Jnd in the SSA pathwJY of cJTcinogencsis epigenetic 
inJctivJtion of speci fic tumour supprl'ssor genl's, p161NK411 Jild IGFBP7, enables 
BRAF mutJllt cc lis tu evade ollcogene-sem.'sccncc ]22 1-224] Jild .lllows fur 
uncontrolled proliferJtion and prog ression of seTT,lIed lesions. Although the SSA 
pathwJY is JssociJted with microsJtelli te-instJbility, it JPpears IhJI epigenetic 
inJcti vation of MLI /1 is a l.lte-occurring s tep in the mJlignanllrJnsformation of 
SSAs ]225, 226]. However, not .111 SSA pathw.1Y neoplasia exhibits micros,ltdlitc-
instJbility and there is a subset of tumou rs that .lre ClMI'-high, V600E BRAF and 
microsJtellite-siable. 
The traditional SCTTJtcd Jdcnoma (TSA ) pJthway is characterized by .m 
,1ssoci.ltion betwecn low-level CIM]" micros,ltcllitc-inslability low (MSI-L), 
ll1elhylJt ion of MGMT, Jlld mUIJtions of KRA S [206, 227-23 1 [. The precursor 
lesions thJI Jre JssociJted with this pJthwJY arc unclear, but it hJS been 
proposed th'lt they may represcnt J hybrid or fu sion betwcen lesions ,lssoci,l ted 
with both the trJditionJI adenomJ-cMcinomJ and scTT.lted pathwJYs [216, 232[. 
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].4,3.4 St'l"r(lft'l/ Pl/f/Il\'{/)' Risk P{I('/OD' 
2.4.3.4.1 EII1.jrollmcllial RiskFIlc/ors 
Evidt!llcc suggests thilt the etiology of the serrated neoplasia pathway is 
associated with certain environmental risk facto rs. Thesc include a low dietary 
consumption of cillcium, folilte, ilnd fioc'r, ,1S wt!1I ilS a high dietilry consumption 
of filt, alcohol and me,lt 1233-237]. Filctors associated with insulin resistance 
syndrome, such as obesity ilnd smoking, Me also linked with the sCHilted 
pillhway 1236-248]. Thl.'rc is some evidence 1236] 10 suggt!st Ihilt risk factors for 
right-sided versus left-sided serrated polyps Illily be different, which is likely due 
to the heterogenous Ililtu re of serrilted polyps. 
Smoking is tht! strongest environment,ll risk fa ctor ilssociilted with the 
scrrilted pilthway. A substantiill body of evidence 1249] links smoking with th., 
risk of developing colorectal C,lnCef. Recently, however, the ,1ssociiltion between 
smoking ilnd colorectal Cilncer has been recognized to be gre,ltest for thosc with 
hyperplilstic polyps 1242, 243J and for pntients whosc tumours display 
microsntt!lIite-instnbility [244, 2451, ClMP nnd the V600E 8RAF mutntion [237, 
245-2481. Tht! mt.'Chanisms by which smoking influenct!s tht! developmt!llt of 
scrrilted p.1thwilY co[orecl.11 Cilncer is poorly understood, but it may be rdiltcd to 
,1 link rl'Cl'ntly found [76, 771 behvl't'n smoking and increilSt.'<I epG island 
rnethyliltion. It mily also be rdilted to il findi ng [250, 2511 that cig.lrette smoke 
activ<ltes the aromatic hydrocarbon receptor, which can lend to mdhylalion of 
p16 .lnd p5J 
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2.4.3.4.2 GmdicRiskFllctors 
A genetic pred isposition to develop colorectill Cilncer viil the serrated 
pilthwily hils been suggested [1 84J. Evidence for iln inherited predisposition to 
develop colorectill cancer via the serrated pathwilY is linked to two colorectal 
Cilncer prt:'disposition syndro mt:'s, namely hyperplastic polyposis syndrome and 
serrilted pathwilY syndrome [1 85 [. The genclic cliology of Hl 'S is unknown, but 
it is cl inicillly identified by hilving: a) a t leilst five histologically diilgnosed 
hyperplastic polyps proximal to the sigmoid colon, two of which Me greilter th,m 
IOllllll in diillllcle r; o r b) ilny number of hyperplastic polyps occurring proxim al 
to the s igmoid colon in iln individual who hilS a FDR with hyperplastic 
polypOSiS; or c) more than 30 hyperplastic polyps of ,my size but dis tributed 
throughout the colon 12521. HPS is il rare condition ilnd is typicillly diagnosed 
rdatively late in life (SO - 70 yeil rs of ilge). A family his tory of HPS has b(X'n 
reported in some families, which suggests il possible genclic predisposition [2531 
The diltil is insufficient to estilblish the risk of developing coloreclill Cil ncer in 
those with HPS, however the risk is thought to be greiltest in piltients with large, 
.l typiml ilnd d ysplilstic polyps. Furthermore, it is suggested thilt Ihe precursor 
It.~ i on,.; associakd with HI'S harbor the c.lpacity to undergo rapid malignant 
tfilnsformiltion. One report 11 861 described three HF'S patients who dew loped 
coloredill ca ncer d ..... pite 2-yeilfly colonoscopy. Another report 1254J has 
suggested that 3-yearly colonoscopy surveillilnce \VilS insufficient fo r some 
families with serrakd polyps 
Young d a/ 12551 described families who were affected by colofl'<:till C.lnce r in 
il milnner consistent with ilutosomal dominilnt inheritilnce. Furthermore, filmily 
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members exh ibited a predisposition to develop sessile serrated adenomas ,md 
adenocim;inomas that had clinicopathological fe:ltures consistent with the se..,sile 
serra ted :ldenoma pathway - proximally located, MSI-variable, V600E BRAF 
tumours. These observations suggest that the development of serrated pathway 
colorectal c;mcer may be ca used by penetrant inheri ted fiJ ctors in SOllle p.ltients 
Young ('/ ill referred to this strong predisposition to develop serrated pathway 
colorectal cancer as serratcd pathway syndrome (srs). 
Further ev idence for a genetic predisposit ion to develop coloredal cancer via 
the serrated pathway comes from two rcccnt studies [21 1, 214 [, which discovcred 
an elevated fami ly history of colorectal canccr associated with patients who have 
sessile serra ted adcnomas or tumours with the V600E mutiltion, both of which 
are strongly ilssociated with the sessile serrilted ildenoma pathway. In an 
unselectcd series of patients undergoing cotonoscopy, p<1lients with sessile 
serrated ade!1olllils, compared to patients with other colonic lesions, were more 
likely to have il family history of colorectill cancer (42'", vcrsus 2S'f,,; r > 0.0:;), ilnd 
a g reater polyp burden (P< O.DOI) [214]. The second s tudy [21ll, a large 
unselected ptJPulation-ba!jt;'d study of colorectal cancer pat ients, found that 
amongst patients with MSS tumours, pillients who hild il V600E BRAF tumour 
were significantly more likely to hilve il filmily history of colorectill C:lllcer (OR, 
4.2; 95'f" e l, 1.65 - 10.84). However, the ilssociation with filmily history WilS not 
obse rved for piltients who hild MSI-H tumours. 
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2.4 .4 MLlTYIl-A:isocia /ed PolYII()sis (MAP) 
The base-excision repair (J3ER) system is a 'care-ta ker' mechanism that 
functions to detect .1nd rep.1ir DNA d.1mage caused by oxidative dama),;e [2561 
Although numerous proteins are involved in BER the MUTYH protein is critical 
for the dete<:tion and removal of adenine residues that incorrectly pair wi th R-
oxo-7,R-dihydro2'deoxyguanosine_ Failure to repair this mispai ring results in 
distinctive G:C to T:A transvl'rsions <It the nex t round of DNA replication. 
Germline MUTYII mutations were discovered in patients who clinically 
prescnted like FA!', but h<ld an autosomal recessive p<lttern of inherit<lnce, <lnd 
did not harbor pathogenic mutations of the Af'e gene. Further examination 
rl've,lled characteristic somatic G:C to T:A mut<ltions in the tumours of thl'S€' 
p<llients, which implicated the BER system .1nd Ml/TYH gene specifically. To 
date, more than 80 mutations of MUTYII have been catalogued, but two spt.'<:ific 
mu t<llions (Y165C <lnd GJ82D) account for <lpproximately 8070 of all mutations 
reported in Caucasian populations 1257, 258] 
MUTYH-associated polyposis (MAP) is a recessively inherited condition that 
preSl'nts s imilarly to FAP and AFAr. However, it is highly variable and 
diagnosis is typically at a later age than FAP. No other (lcfining fc,ltures of MAl' 
h<lve been identified, but some ex tra-colonic manifestations have bL>en observed 
12591. Thl' findings of a reCl'nt study [2601 of 276 MAP p,lIients, suggested that 
the syndroml' is also associated with an elevated risk of duodenal. OV;;JTi<ln, 
bladder <1I1d skin C<lncers. Several population-based case-control studies ]38, 261, 
262) h<lvC estimated that 0.4% - 1_070 of colorecta] cancer patients arc carriers of 
homozygous or compound heterozy),;ous MUTYH mutations. Homozygous and 
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compound heterozygous mutation carriers appear to be at substantial risk for 
developing colorectil l cil nccr. A recent ~tudy [38J found <Ill ildju~ll'd odd~ rillio of 
18. 1 (95% CI, 2.5 ~ 132.7) for the odds of developing colorectill C<lllcer. Howewr, 
the cancer risk Jssociilll-ci with hctero~ygous MUTYH mutiltions hil~ bcen il 
subject of debate. SeverJI studies ]261, 263, 264] have linked hcterozygou~ 
mutJtion cilfriers with a non-significant increase in colorect,ll cancer risk, but a 
recent lilfge case-control study [38], which screened for J larger number of 
MUTYI-I mutations than previous stud ies, reported thilt heterozygous carrier~ 
were at increased risk of developing colorectal cancer (Adjusted O R, 1.48; 93'}!, CI, 
1.02 ~ 2.16). The ca ncer risk Jssociilled with a heterozygous Ml/TYH mutation 
carrier is now widely acknowledged as a 10w-penetr,lIlt risk allele. 
1.4.5 Familial Colorer/al GHlC", Tyl''' X (FCCTX) 
In 1991, the ICG-HNI'CCl'Stablished clinical criteria (Amsterdam [Criteria) 
to identify high-risk color('ctal c,lncef f,lmilies for gene idcntificiltion purposes 
In order to fulfill the Amsterdam I criteria a family needed to sa tis fy all criteria' 
a) three cases of histologicJI!y verified color&tal cancer in two generations, with 
one affected being a FDR of the other two, and b) one patient diagnosed with 
colorect,ll cancer before the age of 50 yeilfs, ilnd c) Familial adenomatous 
polyposis mLlst be ruled out. The clinical criteria ilfe sti lluscd to identify 
potential Lynch sy ndrome patients, but once the molecular etiology of Lynch 
syndrome WJS discovered, it IVJS recognized thJt not all bmili('s fulfilling 
Amsterdnnl I criteria were affected by MMR gene mutations 
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A semina l paper [37] by Lindor ('f al investigated ruloreclal c,mceT p,ltients 
who fulfilled the AC·] in order to investigate the clinicopathological <lnd cancer 
risk differences betw('('n patients with and wi thout evidence of tumour MMR-
defici,;'1lcy, The principle finding W<lS that patient.-; without MM 1{-ddiciency had 
a s ignificantly reduced familial incidence of colorectal c,mcet (SIR, 2.3; 95% CI, 
I.? - 3.0) compared to those with MMR-deficiency (S IR, 6.1; 95';1, CI, 5.2 - 7.2). 
Additionally, age at colorect,ll cancer d iagnosis was found to be s ignificantly 
l<lter in families of patients without MMR-ddiciency (61 versus 49 years) and 
there was little evidence for developing extracolonic malignancies. The authors 
concluded that AC-I patients without evidence of mismatch repa ir dysfunction 
likely rl;'prl;'SCnlcd a genetically heterogenous g roup of inheritl'd colorl'ctill cancer 
syndromes that arc diologically i1nd clinica lly different from Lynch syndrome. 
The authors identified patients fulfilling the ACI without evidl;'ncl;' of MMR-
deficiency as familial colorectal cancer type X (FCCTX). 
Subsequent s tudies h<lvc reported sim ilar findings <IS Lindor ~, t III [37]. For 
I;'x<lmple, one study [265] COmp<lrl-d MLHl <lnd MSHl mut<ltion carrier>; to 
colorl;'d<ll patients who h<ld a family history satisfyin,c, the AC-I, but who hild 
tumours withou t evidence of MMR-deficiency. That s tudy also found that 
FCcrX f"milies had" later age of onset of colorect,,1 cancer than mutation 
Cilrriers (Median 41 vs. 55 yI;'MS; P < 0.001). Addition<llly, FCCTX p<l til;'nts \\'I;'re 
found to be more likl'ly to h,lVe left-sidl'd tumours (68% versus 147<); I' < 0.01) 
and less likely to have synchronous or metachronous tumour s(t' < 0.017) or have 
extracolonic tumours (I' < 0.001). Notably, the ratio of ,ldellolllil to CMcinom,l 
was higher in those with norm,ll MMR function (I' < 0.03), suggesting thilt the 
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tr;msformation from adenoma to carcinoma W,lS reduced in FCCrX patients 
compared to thost> with MMR-dcficiency. The finding~ of a large prospective 
study [266[ conducted in Spil in, ~uggested that 601<, of pntients with a fam ily 
history fulfilling either the Amsterdam I or II criteria had a microsatdlite-stable 
tumour. Similar to previous findings, patients without evidence of MMR-
deficiency were older at diagnosis (i' = 0.6) and more likt.>ly to have dis tally 
located tUIllOUrs (P = 0.15). The family members of these patients were less 
likely to be afkcted by colorectal cancer (P = 0.011) and had a later age of 
diagnosis (P = 0.036). The au thors of one other study [267] have also reported 
that iI IMge proportion of Amsterdam r cri teria colorectal cancer patients have a 
MMR-proficient tumour (40';;, ). These patients weTe found to be significan tly 
older at diagnosis compMed to patients who had a MMR-deficient tumour (53 
versus 41 years; r < 0.001) and more frequently had left-sided tumours W '" 
0.001). Additionally, filmily members were less likely to have a synchronous or 
Illetachronolls tumour (P < 0.(0 1) or to have an extracolonic tumou r (r = 0.00 1). 
It is speculated that the etiology of FCO"X could be expl il ined by a highly 
penetr,lIlt risk variant, multiple low-penetrant risk alleles, sha red lifestyle f,lCtOrs 
or even statistical chance. However, the accumulating l'vidence suggests that 
FCcrx has numerous etiologies. This hypothesis is supported by numcrolls 
linkilge stud ies [27-3t[ of FCcrX-likc families, which have found linkage to 
multiplc fcgions of the genome. For example, a sib-p,lir analysis [27[ fo und 
evidence fOf linkage to a region on chromosome 9 (9q22.2 - 31.2), in a pattern 
consistent with autosomal dominant disease. Linkage to this region was 
confirmed by two additional studies [28, 29] A high-density genome-wide 
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linbge study [JO [ found linkage to 3q21 - q24. A genome·w id e linkilge analysis 
[JI [ of 30 Swed ish families w ho had dominant colorectal cancer family his tories, 
found no association with the previously described region at 9q22. ]-]owever, 
that study did find st rong evidence for link<lge to 3q2 1.1 - q26.2. Most recently, a 
comp rehensive genome·wide linkilge analysis of seven FCCTX-like families, 
performed by Midde1drop et 111 [268], also fou nd evidence for linkage to 3q, but 
overall the find ings were inconclusive. Collectively, these findings support the 
hypothesis that FCCTX is likely a hett' rogenolls disease 
2.5 Colorrctlll Cli llcrr Screellillg 
Trea tment of colorectal cancer is highly successful if diagnosed in the I;'a rly 
s tages. Five-year survival is approxim<ltely 90% for local ized disease, but 
decreases to 68% for regional dise,lse (Lymph node involvement) and 10% if 
distant metastasis has occurn.'<i [269]. Tht'S(' probabilities highlight the reality 
thM screening and early ddection ,1re critical for positive patil;'nt outcomes. The 
natural history of colorectal cancer includes a long preclinical phase ([0 - 15 
yeMs) and detectable precursor lesions, which provide opportunities for 
screening ,1nd intervention. There is convincing evidence from SeVer,l! 
r,mdomized controlled trials [270-274J that screening and subsequent 
intervention (polypectomy) [educes both the incid l;'ncl;' of colort.,<:tal CanCl;'f and 
colorect<li cancer rdated mortal ity. For example, il s tudy [274[ rl'ct'ntl y 
demonstrated that il screening program that used repeated annual o[ bicnni,11 
glliliac fl;'c.lll)ccult blood tests (FOI3Ts) and endoscopic follow-up of positive 
il'sts, reduced colorectill cancer mortality by sixteen percl;'n t (95,/" CI, 10% - 22';:,) 
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after 12 - [8 years. Unfortuniltely, despiit! the benefits of screen ing. illilrge 
number o f adults are non-compliant with cu rrent screening recummendiltions or 
have nt;vt;r received ilny form of scret;ning at all [275, 276[. [n 2006, ilmong US 
adults aged 50 ye.us and older, the prevalence of screening with an endoscopic 
procedurt; in the previous 10 years was just 56.3% [275[. Furthermore, screening 
prevalence is significantly lower in some ethnic minoritil's. in lower 
socioeconomic classes and in the uninsured [276]. 
[n an effort to promote screening and to provide consensus evidence-based 
screening recommendations, several organizations hilve issued joint guidelines 
for colorectal cancer screening ilnd su rwillance, namely, a) The American Cilncer 
Society, the us Multi-Society Tilsk Force on Co[orectal Cancer and the American 
College of r~ildiology [277] and b) Tht; US Preventive Services Task Force 
(USPSTF) [278] 
[n 2006 the American Cancer Society, the US Mu[ti-Society Task Force on 
Colo rectill Cilncer, ilnd the AmeriCiln College of Radiology provided a joint 
recommendation regarding colorectill cancer scrt.'ening and survt;il1ance. [n 2008, 
the group updated its screening .lnd surveilJilnce rc(:ommt.'ndil tions for the Cilrly 
detection of colorcct.ll neoplilsiil [277]. The re.:ommendations for screening 
distinguished between tests that dde.:t adenomatous polyps and tests that 
primilrily detect Cilllcer. For tests that detect polyps and cancer, average risk mell 
and wornen should begin scrt.'en ing ilt age 50 years, with one of the following 
regimens: flexible sigmoidoscopy every 5 yeJfs, double-contrils! bil rium eyt;ry 5 
yeil rs, computed topographic colonography every 5 years or colonoscopy evcry 
10 years For it!sb thilt primilrily detect cancer, any of the following regimens MC 
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recommended: annual guaiac-b.lsed fecill occult blood tl>s t with high sens itivity 
for ca ncer, ilnnuill fecill immunochemicill test with high St.'nsitivity for C.lllct.'r or 
s tool DNA tes t with high sens itivity for cancer (interval uncertain). P<ltients with 
a family history of colorectal C,1/1cer (coloreclillneop!ilsi.l in a I" degr('(' reiiltive 
before ilge 60 years, or colorectal nt.'Oplasia affecting two or more I" degrl'e 
relilti ves at any age) Me recommended to being scr('('ning (colonoscopy every 5 
yeilrS) .1t ilge 40 yeil TS or 10 years before the youngt.'St case in the immediate 
family. 
[n 2008 the US['STF updated its screening recommendations [278]. The 
USI'STF's assessment concluded that the net benefit of scr('('ning WilS high for 
average- risk persons aged between 50- 75 years who followed either a) annual 
high-SOo' ns itivity fecal occult blood testing, or b) flexible sigmoidoscopy every 5 
years - combined with high-sens itivity fecill occu lt blood Il'sting every 3 years, or 
c) colonoscopy evcr to yt'.lrs. The net benefits for individuals 76 - 85 were small, 
and the net benefit of scr('('ning does not outweigh the hilrm for individllills 
greilter than 85 years of age. In addition, the USPSTF concluded that there was 
insufficient evidence to assess the effectiveness of fec,11 DNA tests, and as well, 
concluded that there WilS insufficient evidence to assess the net benefit and harm 
of CT colonography. 
Colorecta! cancer survei llance protocols iHl' ilpplicilble to patients found to 
hawa polyp during screening. Polyps are a s ignific.lnt risk factor for colort.'Ctill 
cancer and therefore decreilscd screening intervals are recommended for patients 
found to have polyps. Surveillance guidelines have bt. ... n developed to identify 
p,ltients thilt ilre at high-r isk of neoplasia recurrence from those who arc low-risk, 
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ilild iHl' bilSt.'d on studies that haw ch.lrilcterized polyp feiltures predictive of 
future recurrcncc. For cXilmple, il study [279[ of 3, 121 ilsymptomiltic veterilns, 
aSed 50 - 75 years, thilt were screened ilnd had repcilt eXilminiltions 
.lpproximiltdy 5.5 yea rs lilter, found thilt patk'nts who hild mult iple tubular 
adenomas, ill .. rgt! tubular adenom .. (> I cm), villous histology o r .. n adenoma 
with high~grade dysplasia at baseline, were s ignific.lntly morc li kd y to devdop 
Further to its recommendiltions for screening, the American Cmcer Society, the 
US Multi-Society Tilsk Force on Coloreclill Cilncer, ilnd the American College of 
R .. diology jointly issued a slatement regarding slITwillanCt' [277[ . I'atit!nts Me 
ft.'Commended to h .. ve repeat screening colonoscopy ilt \0 yeil rs if no neoplils i.l is 
found ilt initial screening; Ikpeat sCR'Cning il t 5 years if I or 2 small « !em) 
tubular adenomas are found; and 3-year inH'fv.ll colonoscopies if at increilSt.-d 
risk for advanced Ic-sions, definl'd ilS h.wing an ildvilnced lesion (> Icm polyp, 
villous histology, Of high-grilde dysplasia) or 3 or more .. denom.ltous polyps. 
Al though the guidelinc-s were evidl'llct!-bascd, a T\!CCnt study [280[ has 
(Iuestioned the evidence th.lt has formed the TilSk Force's surveill .. nce 
recommendations. Th is p.lrticulilr stud y [280[ evaluilted the .. bility of the current 
surveillance guidelinc-s to sl r.lIify high-risk from low-risk patients. In t,905 
pilticnts who had an adenomil at bilseline colonoscopy, the probilbility of 
ildvilnCt'd adenoma recurrence at 4 years was 0.09 (95';;, Cl, 0.07 - 0.11) among 
piltients w ith high-risk adenomas ilt baseline and 0.05 (95% 0, 0.0'; - 0.06) among 
those wi th low-risk adenomas ilt baseline. Although this differcnce is s t,ltisticillly 
signific,mt, it has oc'en argucd IhM the result mily not be clinically relevant. 
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Furthermorl', thl' study found that only the villolls histology component of the 
surveillance guidelines was significantly predictive of ildvilncl,d ildenoma 
recurrence in a multivMiate model. Adenoma size, high-gr<lde <lnd nlultiple 
ildenomils were not independently predictive of recurrence. This result also 
questions the predictive v,llue of the current surveillilnce guidelines to effectively 
discriminate between high <lnd low risk p<ltients. 
In <lddilion to <ldenomatous polyps, vilrious other colonic It.'Sions ilfe bei ng 
rl,<:ognized ilS precursor lesions with malign<lnt potential. Two types of lesions 
thilt hilve been incre,lsingly impl ic<l ted in cMcinolllil predisposition Me the 
advanced serr<lted polyp and non-polypoid colorect<ll neoplasi<l (NP-CRN). The 
advana..x\ serr<lted polyp, which includes Sl'Ssile serr,lled <ldenOm,ls, serrilted 
adenomas <lnd mixed polyps are now recognized to hilrbor malign<lnt potential. 
Current opinion suggests thatlMger serrah .. '<i polyps located in the proximal 
colon should be removed, but thai smililer polyps loe,lted in 111l' d ist,ll colon ilTl:' 
less likely to undergo millignilnt transformation. 
Non-polypoid colorectal neoplasi<l (NP·CRN) describes gilstrointestin,ll 
lesions th.11 Me depressed or flat ilnd only nxently was their malignant potenti.11 
.1cccpted 1281, 2821. Reports 12831 from Asian populntions in the 1980s and 90s 
suggested Ihilt NP·CRNs were previllenl and h.ld m.1lign.1nt potenti.1l, but not 
until fc<:ently did a study eXilmine the prcv.1lence of NP-CRN in.1 North 
AmeriCiln popul.1tion and Ch.1 f.1 cterize their associ.1lion with colorectal cancer. 
In 2008, a cross-sectionill study 12841 of 1,819 piltients undergoing colonoscopy 
found the proportion of NP·CRNs to be 9.4% (95% Cl, 8.0'lo - 10.87<. ) of ill! 
identified colonic polyps. Importantly, NP-CRNs were fOllnd to be much more 
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likely to contain c,ucinoma than polypoid lesions (OR, 9.8; 95% CI 3.9 - 24.4) 
NP-CRN presents a potentially challenging diagnostic problem. It appeiHS that 
thl'sc lesions arc prev,llent and h.ubor malignant potential, but they are difficult 
to detect with current optiC,ll screening moclillities. Additionally, resection of 
NP-CRNs is challenging and the currt'nt evidence regarding recurrenCl' risk is 
insufficient. For these reasons it has been hypothesized 12831 that NP-CRNs may 
explain a substantial proporti(Jn of interval c,lncers 
Current screening practices are effective, but thefC ,lre deficiencies in 
sc~ning participation, infrastructure and knowledge. Although screening 
prevalence is increasing in the United States, it re lll<lins low. In <In effort to 
improvl' sCrl'Cning participation, organiz,ltions h,lvc isslI('(\ consensus s tatcll1ents 
that provide al ternati ve sCrl'Cning strateg ies for p<ltients <lnd their physici<lns. It 
has been suggested [275[ that particip,ltion in scrcening could improve with 
incre.lsed public awaren('Ss, incentives for he.l lthcare providers to recommend 
screening, improvements in infras tructure to rl'mind patients ,1~)Ut screening 
and increased access to care. Funding clinical resea rch should also be a priority, 
as there remains an uncertainty regiHding lx'St clinical pr,lctice, the effectiveness 
of emerging novel screeni ng modalities (eTC and Stool DNA tes ts), the best 
markers to s tratify high-risk from low-risk patients, ilild the s ignific.l llce of non-
polypoid and serrated lesions. 
54 
Chapter 3 - Research Methods 
3.1 f'ntil'IIts fllld Metilods 
This study prospectively idl'lltified inckil'nt coloreclill cancer patients from 
the Newfoundland Colorectal Cilncer Registry (NFCCR). Patients were eligible if 
diilgnOSt'd with colorectill cilrcinomil (lCD-9; colon IS3.0 - 153.9, l'xcluding IS3.5 
(ilppendix); Rectum 154.0 - [54.1) bi!tween JanuMY I, 1999 ilnd December 31, 
2003, and if they were less thiln 75 yeilTs of age at diagnosis. From I, [73 
identified eligible p;]tient~, 750 (64%) patients or their proxy consented to ta ke 
pil rt in the study. Study controls were identified through filndom digit diilling 
,md were frequency matched to patients for s;.'x and S-ye<lf age strata. from 1,603 
potenti,ll1y eligible controls identified though random dialing, 44.8',1" (n = 717) 
agreed to pilTticipate in the study 
I'atients were ,1sked to provide ,1 blood silmple and to grilnt permission to 
access medical records and tissue blocks. Biological specimens provided by 
patients had undergone a series of molecular analyses; which included testi ng for 
tumour microsatellite-instability (MSI), immunohistochemistry (ll-Ie), MLI f1 
promoter methylation, p. V600E BRAF mutation (V600E BRAn, and testing for 
mut,ltions in mismatch repair (MMR) genl's. MSI status WilS 'lssigned ilS MSI-
high (MSI-I-I, >30,%, of markers tested unstable), MSI-low (MSI-L, 1O'}I, -30'}l, of 
m;]rkers unstable), or microsatellite stable (MSS, < 10'f" markers unstable); 
however s ince only a smal l numbi!r of tumours were identi fied as MSI-Low we 
combined them with the MSS tumours. Thus, we assigned tumours ,1S {'Hher 
MSI-1-I (>30';;, of milTkers unstable) or MSS (<30 'f" of markers unstable). DNA 
from patients who fulfilled clinical criteria for familiill adenomiltous polyposis 
WilS le~ted for APC mutiltions; first for those mut,ltions that were previously 
observed in Newfoundland; then by sequencing to identify o ther APC mutations. 
Addilionillly, ill1 patients wcre tested for MUTYH mutilt ions. I',ltil'nts who h,ld 
iln APC or AMITYII mutiltion, or who sil tisfied clinic.ll criteria for FAP or MAP, 
Wl'Te excluded from this study. 
Pathology was reviewed for all ilvililable tumours. One representative 
tum ou r slide from cach patient's tumour had been reviewcd and scored for 
several histological features, including Crohn's-like lymphocytic reaction and 
tumour-infiltra ting lymphocytes (T ILS), ilS described previously [285[. Tumour 
grade and histology were determined from the originill pathology reports. 
Tumour location was obtained from the records of the Newfoundland CilllCl'r 
registry. Proximililociltion was ddined as proximal to the splenic flexure. 
Mucinous component WilS defined as the presence of ilny mucin dissecting into 
stroma surrounding a tumour gland. This definition includes tumours with il 
mucinous hi stology, but also those with hi stologic heterogeneity, in which any 
iHeil of the tumour displilYs dissecting mucin. The OCCllrrence of a synchronous 
or metachronous tumour is referred to as having multiple tumou rs 
Patients and controls were asked to complete il filmily history C]ul'stionnaire 
(FHQ). In formati on obtained from the FIIQ enilbled pedigrees to be constructed. 
The cancer his to ry of each family member was recorded ilS follows: the Cilncer 
status (,lffected: Yl'S or no), thl' type of Cilncer, and age a t diagnosis, or the age at 
last follow-up or de,lth if unilffectcd by Cilncer. Index pJtients ilnd their families 
were excluded from the study for being non-infonniltive if >50% of first-degree 
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rd,lti v('S (FORs) wer<' missing diltil necess.lry for stiltis ticill ilnalysis (e.g. patient 
<lge could not be caJculilted). 
The pedigree for eilch indl'x patil'nts W,lS assessed and piltients were 
identified <lS high-, intermediate-, or low-risk <l ccording to the following filmil y 
his tory criteriil. High-risk piltients were idl'lltifil'<l as those who Wl're ilffl'cll'd by 
Lynch syndrome O.e. harbored a p<lthogenic mismatch repair gene vilriant) or 
who otherwise fulfilled tht:' filmilial coloreclill cancer type X (FCCTX) 1371 or 
modified-FCCTX (M-FCCTX) criteriil, both of which ilre based on the Amsterdilm 
I cTiteri<l (AC-i). The FCCTX cTiter;<l [371 are as follows: 
At leas t three rcliltives affected by CRC; with one affected rela tive 
being <l FOR of the other two affected. 
At leas t two successive generations affected by CRe. 
iii. At leas t one relative affected by CRC diilgnos('d before the age of 50 
yeMS. 
Index patient' s tumour is microsiltellite-stilble. 
The M-FCCTX criterion climiniltes the requirement for ,1 colort'ctili CilnU'T 
diilgnosis before 50 yeil rs of ,1ge. tndex piltients not fulfilling high-risk criteriil, 
but who hild at least one FOR <lffect~1 by colorectill cancer were designilted ilS 
intermediate-risk patients. Index p<ltients with no FORs affected by colorect.ll 
cancer were design<lted as low-risk patients. A filmily history of colorectal C,lIlCeT 
was defined as having at least one FOI{ affected by colorec!<ll cancer at <lily <lge, 
in addition to the index patient. 
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P.ltients and controls were also .1sked to complete personal history (I'HQ) 
and food frequency (FFQ) questionnaires. Participants were asked .1bout 
demographic factors (age, sex, and highest education attained), anthropometric 
variablt!s (height and weight), and mt!dical history. l'ilrticipilnts were .lskt .. d 
ilbout their usc of illcohol. tobilcco, non-steroidill anti-infl.lmmatory d rugs, 
die tary supplements (i.e. multivitamin, c.1lcium and folilte) and about their 
weekly die tilry consumption of nleil!. fruit ilnd vegetables. Their leveillf physical 
ilctivity ilnd whether they p.lrticipiltcd in coloredill c.lllcer scR'Cning WilS illso 
investigilted. Women were asked about their menstrual SliltUS, as well as their 
use of hormone contraccptivl'"S ,lnd hormone rt!plilcement therapy (H RT). 
This thes is utilized two different study designs in order to meet its objectives. 
A cohort study design W.1S used to ilwl'"Stigatt! the risk of cancer in families of 
patients defined ilS high-risk and intermediate-risk, .1S well as in piltient 
subgroups defined by spt.'<: ific clinical illld molecular characteristics. This thes is 
also utilized a case-control study design to investigate the ,lssuci.1tion between 
certain dietary I lifestyle factors and colorcctal cancer. Ethics .lpproval for th is 
resc,lrch projl'Ct was obtained from the I·tuman Investig,ltion Committee of 
Memorial University. 
3.2S ,atis ' ;Cil I A lIll /ys ;s 
Descriptive analyses were conducted and comparison of continuous variables 
was analyzed by either independent samples t-test or one-way ANOVA. 
Categorical v.lriabk'S wefe analyzed with eitht!r Fisher's exact tl'St or Pearson's 
ch i-square test. Cox proportionil! h.1Z,lrd moot'ls l'Stimilted hilzard r.1tios (H R) 
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for developing c .. ncer in fir'St- dl'grce rciatives. Index p,ltients were excluded 
from the estimiltes of cancer risk. Age at di ilgnosis or ilge ilt last follow-up was 
used ilS the time variable. Log minus log It'st of proportionality was used to test 
the assumption of proportional hazards. The sex of firs t-degree rel<ltives (FDRs) 
w"s entered as .1 stratific,ltion vil riilble. For filmilies satisfying the FCcrX Jl1d M-
FCCrX criteriil, the un<ldjusted estimJte of canccr risk W,lS b<lst.>d on illl first-
degrl't! relatives and excluded the index piltient. The <ldjusted est imilte excluded 
the affected reliltives who wefe necessary to siltisfy the filmily history aiteriJ. To 
ensure consistency, selection of ilffeclt'd f<lmily member'S for exclusion W,lS 
determined by identifying the eilrlil'sl ilffected relatives thilt s..ltisfied the FCcrX 
critcri<l (trind of affected relatives). The index p<ltient was always identified ilS 
ol1eofthe threeilffected 
The cumulative lifetime risk «75 ye<lr'S of age) for developing colorectal 
cJncer in first-degrt.'t' rcliltives was estimilted by Kapliln-Meier survival ilnillysis. 
Standardi zed incidence riltios (SIR) for CRC in FDRs W,lS cilkulilted using 
I'AMCOMP software 12861. The SI R compares the incidence of C1{C in the study 
cohort to .1 popuIJtion-based cohort that was obtained from thc Su rveillancc, 
Epidemiology, and End-Results (SEER) 9 cohort [2871. The SIR is obt.lined by 
d ividing the number of observed C<lses of CRC by the "expected" number of 
c"scs. Index patients were excluded from the estimate of Cilncer risk in family 
members. 
A binilry logistiC regression model WilS utilized 10 identify clinicopilthologic<ll 
fea tures th,lt were ilssociated with familiill colon.'Ctal cancer patients. The 
associiltion betwl'Cl1 clinicopilthologic,11 fCiltures and patients who were st riltified 
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by the moll'cular fea tures of their tumour was estimated u~ing odds ratios (OR) 
that were calculated from multinomial logis tic regression models. 
Comparison between controls and co[orecta[ canCl'r patients stratified by the 
V600E BRAF mutation was estimated using odds ratios that were calculated from 
univariate multinomia[ logistic regression models. The associ,ltion between 
di,lbetes, smoking.. NSAIDs, BMI and co[oreda[ cancer was l'stimated using 
adiusted odds ratios that were calculated from multinomial logistic regression 
modds. Pott'ntial confounders were evaluated by testing their sta tistical 
significance in a univa riilte regression ilnalysis. Variables that had a sign ificance 
of P<O.20 were identified ilS potentiil[ confounders ilnd were included in the 
multivariate models, regardless of thdr statistic,li signific,llKe in the final 
regression model. Missing V.l[Ut'S for continuous and categoric,ll data were 
replaced by the sex-specific mean ilnd mode, rt.~pectively, of the non-missing 
data . Sta tisti cal test fo r trend was calculated by entering the ciltegoricill t'xposure 
vilriilblt' as a conti nuous variable into the logistic regression model. 
1\[1 J1 values were two-sided ilnd p ,;; 0.05 was conside red sign ificant. 1\[[ 
analyses wefl' performed with the Predictive Analytics Statistics Softwa re 
(PASW) paCkilgt', version 18.0 (Chicago, IL). 
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Chapter 4 - Results 
4.1 Tire Study Poprli(ltiQn 
AscertJinment of the study populJtion is depicted in Figu re 1. Written 
conso..'nt hJd lx'Cn oblJined from 64% (n = 750) of eligible colorect.11 c,mer 
pJtients. Consenting p.1tients were excluded: if they hJd J personal or famil y 
history consistent with fJmiliJI Jdenonhltous polyposis (n = 7); if thd r f'11l1ily 
history WJS non-informative (Le. missing cri tical informJtion to eVJluJte fJm ily 
history) (n '" 116); or if the micros.'1tellite-instability (n = 40) or V600E BRAF 
mutJtion stJtus (n = 34) of their tumour W,lS unknown. The fina l study 
population (n = 553) represented 47% of all eligible and consen ting colorectal 
cJncer p.1tients. 
Eligible study controls were contJcted (n = 2, 168) Jnd 74% consented (n = 
1,(03) to participJte in the study. Controls were l'xeluded if they did not ro~turn.1 
completed personJI history questionnJire (n = 890). The finJI control study 
population (n = 713) represents 33'7<, of eligible Jnd consenting con trols. 
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Figure ] I\sccrt<linlncnt of thl;' s tud y population. 
G2 
4.2 Epidemiology 
Index patients were stratified according to the micros<ltl'llite-instability ,lIld 
the V600E BRAF mutiltion (V6UOE) s tiltu ~ of thei r tumour, as well as accord ing to 
whether they wefe affected by Lynch syndrome (Figure 2). The miljority of 
patient tll!llOUrs wefe MSS (89%) and the remainder MSI-J-I (1 1%). The 
prevalence of the V600E mutation in the study populiltion was 1 [.8% (n = 65). In 
MSS tumOUfS, the incidence of the V600E mutation WilS app roxim<ltl'ly 8%, 
whereas in MSI tumours it w<ls44%. Amongst MS1-H tumours, [7 wefe 
associated with patients who h,ld il pJthogenic MM I{ gene vilriJnt, 27 hMbored 
the V600E BRAF mutation <lnd the remaining 17 were BRAF WI. The molecu lar 
pathology dassific.ltion was unde<lr for these remilining 17 piltient tumours 
(shaded in Figure 2), and these p.ltients wefe excluded from further ilnillysis. 
Tumours from index patients identified as "possible Lynch syndrome'· (n = 9) Me 
deficient in at least one MMR protein on [He ilnd the MUll promoter WilS 
unmdhylilted (data not shown). Patients identified as "possible serrated 
pathWilY" contained a color('ctal tumou r that was hyperrnethylated at the MLJ-fl 
promoter 
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Fi gure 2 ClilSsific,1tion of the study population ilccording to moleculilr pilthology. 
A descriptive ilnillysis of the clinicopathological features of index patients 
and their family his tory is presented in Table 4.1.1 . The mean age of diagnosis 
for index patients is 61 ye.1rs, and patients were more likely to be male (60.3'/., ), 
,md their tumours werc more likely to be located in the d istal colon or rectum 
(57.0'/., ) rather than the proximal colon. Fnmily his tory wns evnlunted by 5('ver.11 
criteria. The proportion of index pnticnts who had history of colorectal cancer 
(i.e. ;-,: I FD1{s .l ffectt.>d by colorectnl e .. neer) was approxim .. tely 32'/., . A mueh 
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smililer proportion of the study populiltion hild il f.lmil y history thilt S<ltis fied the 
Amstcrdilnl I critcriil (4.9",{, ), Amongst those who Ihld il f'lmily his tory s'ltisfying 
the Amsterdam I criteria (n = 27), 15 had a microsatdlitc-stable tumour and were 
unilffecll'd by Lynch syndrome, thus siltis fy ing the criteriil for FCCTX. These 
FCCTX patients accounted for 56% of piltients mccting the Amsterdam I criteriil, 
ilnd for 'lpproximiltdy 3'Y., of the entire s tudy populiltion. In ilddition to piltients 
who siltisfied the Amsterdam I criteriil, we identified an ildditionill 16 high-risk 
patients, identified as M-FCCTX, who had a family history cons istent with 
autosomal dominant disease, but who did not satis fy the Amsterdam I criteria 
beC.1USt' of the age criterion (i.e. ilt leils t I FOR ilfk'Cted by CRC less th.ln 50 ye,lTs 
Ofilgc). 
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I'iltients were excluded from this study if the molcculilr pilthology (i.e. MS[ or 
V600E stiltUS) of their turnOllr WilS unknown (n = 74). A description and 
COmpilriltive ilnil[ysis of thesc pil til'n ts is illsa p rescnted in TJblc 4.1.1. t'iltil'nts 
who were excluded were not significilntly different from study pilrticipilnts with 
respect to filmily history (P '" 0.35), which is the primMy outcome under 
inVl'stigiltion. However, excluded pilt ients wefe found to be significilnt[y 
different with respect to other vMiables. 
4.2111i1rri tl'tI C% recta l Cmrcrr 
4.2.1 f-iisir -Ri,kPaticllts 
Approximillely 9% (n = 48) of il[[ index patients were identified as high-risk 
piltients and were either ilffcded by Lynch syndrome (n = 17) or s.1Iisfit;>(\ tht;' 
rccrx (n= [5) or M-FCcrX criteria (tl = 16). A descriptive ilnd compilriltive 
ilnillysis of these piltients is prescnted in TJb [c 4.2.1. Lynch synd rome piltit;'nts 
ilre chilfilcterizt;'d by hilving iln e<lf[y ilgt;' d i ilgno~ is of co[orectil[ Cilnct;'r (mt;'a n = 
51 yrs) ilnd il high incidence (4 1%) of multiple tumours (i.e. a synchronous or 
mctachronous colorectill tumour) 
The phenotype ilssociilted with FCcrX pi1lients \\filS significilntly different 
when compa red to Lynch syndrome patients. FCcrX pi1lients were s ignificilntly 
oldcr il t diilgnosis (f' = 0.02), less likely 10 ha ve multiple tumour~ (P ". 0.04) ,md 
more likely to hilve il tumour located in the dist ill rillher than proximill colon 
(64';':) vs. 47';;,), ,llthough this result WilS not s tiltistically s ignificilnl (P = 0.46). The 
c1inicopilthologic<l1 phenotype ,lssociilil'd with M-FCCrX, howewf, W<lS si mililf 
to FCCTX. ThcS(> two piltiel1t subgroups were nol stilti sticillly diffl'fenl with 
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rt;".;pt;'ct to the occurrence of multiple tumours (P .. 0.48), tumour loca tion (P .. 
0.27) or stage of discast' (I' == 0.57). Patients iden tifil'd as M-FCCTX IVcre, 
hOIVt;'ver, slightly older at diagnosis than FCCTX patients (64 yrs vs. 59 yr~), but 
the resul t did not reach stat istical significance (I' .. 0.12) 
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We investigated and compared the risk of developing colorectal CJncer in the 
FORs of high-risk pJtients with time-to-event JIlJlyses (TJble 4.2.2). The lifet ime 
risk for developing colorectJ I C<lncer W<lS gre<ltest in the FDRs of Lynch syndroml' 
pJtients. The lifetime risk for developing colore<:tJ I CJnc('r in FDRs of Lynch 
syndrome pJtients WJS estimJted to be JpproximJtl'iy 50% (LR% = 52';;'; 95% 0, 
38% - 66%). When compared to Lynch syndrome fJmilics, the risk of colorectJI 
Cilnccr in FCCTX filmilies \VilS less (LR% = 351<, ; 95% 0, 23% - 47'1<, ), bu t the 
diffl'TcnCl' was not statist ically s ignificant (1ogrank l' = 0.07). I [owever, the risk 
in M- FCCTX famil ies was sign ifican tly less when compared to Lynch synd rome 
fami lies (LR'J,, : 39%; 95% Cl, 25% - 53%; logrilnk 1' : 0.(03). 
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Figure 3 demonstrilks thilt the greilter risk of developing colorecl,ll Cilner in 
Lynch syndrome families is largely attribut,lble to the occurrence of l'arly-age 
( anCl'fS (i.e. diagnosis < SO years of age) in these famil ies. This is also t rue for 
fam ilies identified itS FCCrX. Howl'vcr, Figure 3 also dl'monst r.lll'S that the 
(.lncer risk profiles for these 3 patients subgroups is very s imiliH after the age of 
SOYCiHS. 
L@<j @nd 
-+- T.ynch ~yndrome 
o FCCTX 
O M- FCCTX 
I\q .. lyr3) at di"gl103b of colorect .. l CanC .. r Or 1 .. 3t follow·up 
Figure 3 The cumulative incidence of co1orecta1 c.1I1cer in first-degrre relatives of 
high-risk piltients. 
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To 'ldju~t for the selection bia~ introduct'd by compilring the risk of colon'ctill 
Cilncer in families identified by a genetic mutation (Lynch syndrome) to families 
identified by family history criteria (FCcrX and M-FCCTX), we excluded from 
the ilnilly~i~ affected filmily memocr~ in FCCrX ,lnd M-FCCTX f'l milies who 
were necessa ry to siltisfy the f.unity history criteria. The adjusted rdative risk 
l'stimilte for developing colorectal mncer in FDRs of patients identified as FCCrX 
(HR ; 0.20; 95% Ct, 0.10 - 0.41; P < O.OO I)and M-FCcrX (HR '" 0. [6;95% Ct, 0.07 
- 0.36; P < 0.001) was significantly lower when compared to Lynch syndrome 
filrni!il's( Tilble 4.2.2). 
4.2.2/II/(:rml'riiatt'-i<iskPlllit'lI/s 
Index piltients who did not fu[fill high-risk criteria and did not contilin il 
MMR mutation (n ; 488), 26% (n '" 127), but who hild ilt least one FDR ilffected 
by color(.'Ctill cancer, were designated ilS interm<.-diatc-risk piltients (Tilble 4.3.1) 
Ind ex piltients without.1 FDR ilffccted by colorectal CilnCl'r were desigllilted ilS 
low-risk patients (n '" 361). We investigated the association between family history 
and clinicopathological features and molecular markers of carcinogenesis in non-
high-risk patients (Tilble 4.3.1 ). In univariate nnnlysis, mod er.lte-risk patients 
were more likely to have multiple tumours (P '" 0.01), a tumour ]()(nted in the 
proximal colon (p '" 0.08), and more likely to have a MSI-H tumour (P; 0.(0 1) 
and a V600E tumour (I' <O.OO[) thnn low-risk patients. Moderate-risk patients 
were also slightly older at diagnosis, but the result wns not statistic,l 11y significant 
(Il trend ", 0.15). However, in multivnri.1le analysis only two features remaine<l 
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significantly ilssociated w ith mod~rilt~-r i sk p<1tients ~ the occurrence of multiple 
tumou rs (odds ratio "" 1.98; 95% G, 1.02 - 3.84; P = 0.04) ilnd th~ pr~scnc~ of the 
V600E mutation (odds ratio ", 2.71; 95% CI, 1.56 - 4.7 1; I' < 0.00 1) 
T,.bl" 4.J.l Clinin'p,lthol<>gi( •• 1 f(, •• t"",s ,'SSo""; •• k-..:l wi th """ high·rbl< n,I",,-'dal "011' ..... " pali."nts wh" 
h~wafamilyhi't "'yofrol""-xt,,lc,'n~r. 
~ 
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We s tratified non-high-risk patients according to the V600E mutation 
s tatus of their tumou r and according to whether or not the patient had multiple 
tumours. In the event thilt il pilt ient had both a V600E ttlmOur and multiple 
tumours (n '" 3), it was decided that the V600E mut.1tion would take precedence 
Accordingly, 63 p<lticnts who h<ld <I V600E tumour were design<lted <IS "V600E ", 
32 p<ltients who h<ld multiple tumors (BRAF 'Nt) were design<l tcd .1S "m ul t iple 
tumours", and p.1tients without either of these fe<ltures wefe designated as 
·'rem.1ining" (n = 393). We compilred the fi ~k of developing colorcct<ll C<lncer in 
FD I{s behvcen these 3 p<ltient subgroups (TJ ble 4.3.2). The haz.1fd for 
developing colorectal cancer was significantly greater in FDRs of patients 
designated as ei ther "multiple tumours" (HI{ = 1.88; 95% 0, 1. 11 - 3.20; I' = 0.02) 
or "V600£" (HH = 2.66; 95% G, 1.83 - 3.86; P <0.001), when compared to 
"remaining" families. 
T.,bl,·4.J.2 TI,,· ,j,. ,>/ " ,1"",,1.,1 c.'"""' in r. "I·J,'~"" ,d.li'~~"1 r~'" h,~ h·ri'. p.,I;"n" ,I,,"tl,'tl ~y th..· VotO.l[ BRAr 
muto'i"n , nd,h<,>«ur,,,,,,,,,,f.n,,,ltiplc ,u m,,",, 
f.",ou,t'>thoiO)\y 
l.itdonk·,,,.,·,, ;m.,,,'tlby "'p l, ,,. Mei""lL,,',,,1"""Iy, ;' 
' II .",,~I r" '~' ,-.I .. " " tc,l b)' C" , R,'~" __ ,~,,, m.~ld 
fOR. 
,.·,i,k 
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The cumulillive incidence of coloreclill Cilncer in FDRs ,lCcording 10 the 
designation of the index patient is prt:'Sented in Figure 4. This figure 
demonstriltes thil t the incidence of colorecta l C<lncer in FDRs of "multiple 
tumors" and" V600E" is greilter, p.1rticul.1r1y ,1fter thl;' age of 50 yl;'<lTS, than in the 
f'lnlily memocrs of p<ltients identified <lS "remilining" 
~ 0 . 20 
(; C. l '> 
~ 0 . ' 
Age (yrs ) a t colorectal cancer o r last follo l<-up 
Figu re 4 The cumulative incidence of colorectal C<lncer in first-degree rel<ltives of 
non high-risk p<llients str<llified by the V600E Bf\AF st<llus of thei r tumour <lnd 
the occurrence of multiple tumours. Abbrevi<ltions: MSS = micros<ltdlite-slablc; 
MSI = micros,ltellite-instability high 
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A comp'Hison of the clinicopilthologica! features of patients identified as 
"multiple tumours", "V600E" and "remaining" patients was in vestigiltcd with a 
multinomiallogislic reg ression analysis (Tab le 4.3.3). Compnred to "rema ining" 
patients, "V600E" pntients exhibited a distinct phenotype and were significantly 
more likely to be fe ma le (P = 0.0(4) and 10 have a tumour locillt.'<i in the p roximal 
colon (/' <0.(01). Additionally, their colorectal tumours were more likely to be 
poorly differentinted (P = 0.02), to contain tumour-infiltrating lymphocytes (P = 
0.0 1) and to have il mucinou~ component (P <0.(01). [n contrast, patients 
designated "multiple tumours" did not exhibit any clinicopa thological 
differences when compared to "remaining" patit'nts 
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4.3 V6QOE C%r(~cta/ Callcer 
To investigiltethe impact of MSI stiltus in V600E colorl:'Ctal cancer, index 
patil'llts werl' stratified according to the microsatelJite-instabi[i ty and V600E 
s tatus of their tumour, as foHow s: 
MSS-RRAF Wt tumour (n "" 454) 
ii) MSS-V600E tumour (n '" 38) 
iii) MS[-V600E tumour (n "" 27) 
The clinicopathological differences between patients stratified according to 
the MSJ and V600E sta tu ~ of their tumours was investigated wi th a multinomiill 
regression anillysis (Tilble 4.4.1). V6UOE colore("\il[ cancer. when compared 10 
MSS-BRAF WI coloreclil[ cancer, exhibited il distinct clinicopiltho[ogical profile 
irrespeclive of MSI status. For ex,lmp[e, V6UOE co[orect,l[ cancer (MSS and MSI 
tumours) WilS significantly associated with proximal tumour location (r < 0.00 1; 
for both groups) and with a mucinolls component (r = 0.02 and [' = 0.001, 
respect ively) when compared to MSS·BRAF WI colorectill cancer. While both 
MSS· and MSI-V600E co[oreclal c,lIlcer pilticnts tended to be femille, the result 
was stiltistically significilnl only for patients who h,ld ,1 MSS·V600E tumOllr (I' = 
0.0 1). However, some c1inicopillhological features were observed to be 
dependent on MSJ st.1tus. For eX.1mple, MSI- V600E colorectai cancer patients 
were significantly older ill diagno~is (P '" (J.U4), more likely to hil W multiple 
tumors (r '" O.(X)9) and their tumors were more likely to con tain tumour· 
infil t rnting lymphocytes (JJ <0.000, when compilred to MSS-BRAF WI CO[Orcclil[ 
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Cilnccr; these fCiltUrcS W,l S not observed with MSS-V600E colorcctal cal1cer. 
However, M SS-V600E coloret::tal c,ll1cer W,lS s ignificantly associ.lted wi th poorly 
diffcrentiiltcd tumours (P =' 0.02) when compa red to MSS-I.lI{AF Wt colorectill 
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Addilionil lly, we h.we investigilted the effect of tumour microsiltellite-
instilbility stiltuS on the association between family history and V600E co1orect,11 
Cililcer (Tilble 4.4.2) . The lifetime risk of colorectal Cilncer in FDRs of index 
p.ltil'llts who hild a MSS-BRAF Wt wilsestimated to be 9% (957<, Cl, 77<,- 11'", ). 
Compared to this, the relative risk of co1ot"\'clill Cilllccr WilS significililtly elevated 
in the FDRs of piltienls who had either il M55-V600E tumour (HR = 1.75; 95% Cl, 
1.12 - 2.72; P = 0.01) or MS]-V600E tumour (H R = 2.18; 95% Cl, 1.42 - 3.34; I' < 
0.001). 
fabl,> ~.4.2 The risk of w lon>("t,,1 (~nrer in first-degTL'" ",I"ti\',-s of index p<lti,-nt~ str,Itif;'-..! by 
the miaos.ltcl1ite-instability ~nd V600£ BRAf mutalion st,ltusof tho.'ir tu mour. 
Tuonou rl'~ t h o l ogy 
------
LR',;;.'(95" !, CIJ liR' (95'j" CIJ 1'1;'/,,1' 
MSI-V600E BRAF 290 2~ 111(10-26) 218(1.42- 3.34) <0.001 
MS5-V600[ BRAF 370 22 15(8-22) l.75 (1 . 12 - 2.n) 
~345 165 9 (7 - 11 ) l.OO(Rd.) 
FDR _ hrst-Jegn.. ... n.·bliw~; Lt. - lill'Iirno.' risk; HR t h.lZ.ud ralio 
• Lifetime risk ('Stim,lt(>d by k,'pl,'n·Mo.'io.'rsun·;val ~nalysis 
" II,l"ard ralio (,,,timat(>d by Cox l{egn..'S~ion model 
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The risk of extracolonic millignanciL'S in FDRs of index patients s triltifi t.>d 
according to MSI ilnd V600£ mutation s tiltUS WilS also investig,lted (Table 4.4.3). 
The incidence of nOn-md.lllOlllil skin cancer was s ignificilntly l'Ievilll'd in the 
FDRs of MSS-V600E colorectal cancer (HR '" 2.61; 951<, 0 , 1.1 5 ~ 5.92)and MSI-
V600£ colorecial cancer p.lticnts (HI{ = 2.81; 95';:, Cl, [.07 ~ 7.4 1) when compared 
to FDRs of MSS-8RAF Wt co[orectal ca ncer patients. The incidence of breast, 
lung and prostate cancer in family members did not differ betwt."t"n these patients 
groups. 
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TJble4.4.3 The risk of extracolonic tumours in first -degree relatives of index p.ltients st r"tified by the m icrosatel1ite- inst~bi l ity Jnd 
V600E 8RAF mut~tion status of their tumour. 
Tumourrathology 
FDRs Risk of Breast Ca ncer Risk of Lung Cancer Risk or Skin" Ca nCH Risk of Pn.stalC Ca ncer 
HR (95~" CJj ,\'0 HR (95% Clj HR (95". Cli 
MS[ -V600EBI<M 290 1.[4(0.41 - 3.20) 2 0.52(0.13-2. ]6) 2.81(1.07-7.-11) 0.65(0.09-4.8-1) 0; 
MSS- V600E BRAF 370 0.71 (0.22-2.26) 6 1.15(0.49 - 266) 
MSS-8RAFWt 1.00 (Ref.) 
FOR = first-degree relatives; H R . Hazard R"tio 
' non-melanoma skin cancer 
• hazard ratio estimated by Cox Regf(';;sion model 
100(Ref. ) 
2.61(1.15-5.92) -I 1.-11(0.50·3.98) 
1 00 (Ref.) 1.00(Ref.) 
To ev.1Iu<lte the mode of diSC'ase inheritance in families of p <l tients wi th 
specific molccu liH pathology, we compared the incidcIKl' of colo rect<ll c<lnccr 
between p<lf('nts <lnd siblings (Ta bl e 4.4.4). The relative risk of colorectal Glncer 
was significantly gre<lter in sibl ings when comp:lred to parents (HR = 3.28; 95;;, 
C1, 1.09 - 9.89) for p<ltients who had <I MSS-V600E tumour. Howcver, this W<lS 
not observed for p<ltients who had a MSI- V600E tumour (HR = 1.23;95'7<, CI, 0.65 
-3.(6). 
Table 4.4.4 The risk of colo1"('ct<l 1 cancer in paJ\'nts .1I1d siblings of index p.lIiellts 
str:l tified by the microsJtellite-instability :lnd V600E BRAF mutiltion st.lt US of their 
tumour. 
Tumour I'athology 
MSI-V600E BRAF 
M5S· V600E BRA!' 
MSS-BRAF Wt 
Type of 
FO R 
Pilfent 
Sibli ng 
[',Hent 
Sibling 
FORs CRC 
at- risk Events Risk of Coloreclill Cancer 
-- --N",- --"'HRC-· ,""95''''"" C"'",------N" 
48 1.00 (Ref.) 
L3S t4 1.23 (0.65 - 3.06) 
71 1.00 (Rcf.) 
151 \3 3.28 (1.09 - 9.89) 
Pnrcnt 866 67 
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1.00 (Rcf.) 
L6t (1.14-2.28) Sibling 2047 
FOR _ first -dcgl"\.'C J\'lntive; HR - ha7-nrd r,ltio 
, Hnz<lrd ratio l'~timntl'd by Cox Ikgression model. 
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4.4 Epidemiologica l Factors lIud V600E Colorectlll Cal/fa 
A descript ion and comparison of colorectal cancer patients and m ntrols is 
prl's<'nted in Table 4.5.1 . I3R.AF Wt colorl'clal cancer p.ltil'llts accounted for 87% 
(n = 436) of the patient study population. Compared to controls, BRAF \Nt 
culoredal ca ncer piltients were signi fic;;ln tly less likely to hilve il college ~~d U C;;lt i on 
(I' < 0.001), to participate in colorectal cancer screening (l' < 0.001), and to take 
calciu m supplement~ (p : 0.005), but had ;;I signific;;lntly greater fiber int;;lke (jJ < 
0.0(1). V600E culorectal c;;l ncer p;;l ti ent~ ;;Iccou nted fo r the remainder of p;;lticnts 
( 13%; n -= 63) ;;Ind were signific;;lnlly older;;lt di,lgnosis (P = 0.01) ;;Ind less 
ed uc,lled (P = 0.002) than controls, but h,ld ;;I gre;;lter fioc'r intake (I' = 0.0]) ;;Ind 
\Vl're more likely to be female (I' < o.oen). Additionally, fem;;l ]e V600E patil'llts 
were significantly less likely to have ever u~d hormone contraceptives (I' < 
0.001) and hormone repl,l(enH'nt therapy (/' = 0.(03) than controls, but were more 
likely to be post-menopausal (100% vs. 87%). 
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The a~sociation between diabete~, ~moking, NSA [Ds and co[oreda[ cancer 
patients who were stratified by the llR.AF mutation was investigak'd with a 
mu[tinomiil[ logistic regres~ion ilnil [ y~is (Tilb[e 4.5.2). In univ;Hiate ana lysis, 
which was adjusted for ilge ilnd sex, V600E co[orectal Cilncer piltients exhibited a 
s ignificant associiltion with diabt-'k's (01< eo 2.53; 95% CI, 1.38 - 4.64), current 
smoking (01< = 2.42; 95% 0, 1.13 - 5.20) and a bordl'rline significilnt ,lssociiltion 
with former smoking (OR = 1.85; 95'f" Cl, 0.99 - 3.44) and N5A[Ds (OR = 0.57; 
95% 0, 0.32 - 1.02). The independent effects of diabetes, smoking and NSA [Ds 
were il[SO investigilted w ith a mul tiv<lfiilte model, which simul taneously ad jus ted 
for age. sex, body mass index, height, l'ducation, fiber, cillcium supplements, 
illcohol ilnd co[ore<:tal cancer screening. [n a llmltivilriilte model V600E colorectal 
cancer piltients wefe s ignificilnt[y associated with diabetes (OR = 2.06; 95% CI, 
Ul9 - 3.88), forme r (OR = 1.85; 95% CI, 0.99 - 3.44) and current smoking (OR = 
2.42; 95% 0, 1.13 - 5.20) ilnd inVl'rsely associated with NSA[Ds (OR = 0.52; 95'%, 
0,0.29-0.95) 
BRAF \-Vt colorecta [ cancer patients exhibited a ~ignificilnt ,lssociation in 
univariate ilnillyses with diabetes (OR = 1.83; 95',1" CI, 1.33 - 2.53), former (Ol{ = 
1,42; 95% 0, 1.07 - 1.88) and current smoking (OR = 1.80; 95ji, 0, 1.26 - 2.57) 
Patients exhibited a borderline significant inverse associiltion with N5A IDs (Ol{ = 
0.78; 95% CI, 0.61 - 1.(0). [n multivari,lte analysis, HR.AF Wt colorectill cancer 
pa tients were s ignific'lIltly associated wit h diilbetes (OR = 1 .61; 95 ';:,CI, 1.1 5 -
2.26), former smoking (OR = 1.36;95% CI, 1.01 - 1.82), current smoking (OR = 
1.72; 95% Cl, 1.18 - 2.52), and inversely associated with NSA IDs (OR = 0.71; 95',1" 
0 ,0.54 - 0_92) Although llot stiltisticilily significil nt, the milgni tude of the point 
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estimates fur the associ,lliun between di;;Jbctes, smoking. NSAJDs, ;'Ind pMients 
who had ;;J BRAF Wt tumour were less th;;J!1 the ;;Jssoci;;Jtion with p;;J tients who 
had a V600E tumour. 
rhe associ.1tion between body mass index and colorectal canccr p.1Ik'nts 
s trMified by the V600E mutation was investigMed with a multi nomial regression 
modd (T;;J bJe 4.5.3). In men, ;'In eiev;'Ited I3M I two yenrs prior to diagnosis \\';'IS 
s ig nific;;Jntly and positively associ;;Jted with BRA F WI colorectal C;;Jnccr (P trend = 
0.02), but not with V600E colorectal cancer (l' trend = 0.38). In WOl11ell, there was 
no evidence tha t an elevated I3Mlwas associated with ei ther BRA F \Nt (P trend '" 
0.30) or V600E colorectal canccr (l' trcnd '" 0.84) 
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T<l ble 4.5.2 The association bt>tween diabetes, smoking, non-stt.>roid.11 anti -inflammatory drugs and colort.>ct.11 cancer 
patients stratified by the I'600E BRAF mutation status of their tumour. 
Controls BRAF W, Tumour V60flE BRAFTumour 
Exposure Univaria te" Multivariate' 
"'''.('0) 
Uni\'arialc" ~ l l11tivarialc' 
No.(% ) No.(%) OR'(95'-:" Cf) OR(95%CI) 01«95%0) OR (95% C/) 
Diabetes 
No 623(86.9) 342(78.4) 1.00 1.00 45(71.4) 
y~ 94(13.1) 94(21.6) 1.83 (1.33 - 2.53) 1.61 (1.15 ~ 2.26) t 8 (28.6) 2.S3 (1.38 _ 4.64) 2.06 (I .W - 3.8~) 
p 0.006 0.003 0.03 
Smoking 
Never 270 (37.7) 123 (28.2) 1.00 1.00 18(286) 
Former 3ol2 (ol7.7) 226 (51.8) 1.42 (1.07 - 1.88) 1.36 0.01 - 1.82) 32 (50.8) 1.85 (0,99 ~ 3.44) 1,84(0.97-3.48) 
Current 105(14,6) 87(20,0) 1.80 (1,26-2.57) \.72(1.18 - 2.52) 13(20.6) 2.42(1,\3-5.20) 2,35(\.06-5.24) 
P-trcnd 0.001 0.004 0.02 
NSAlDs 
No 440(61.4) 291(66.7) I.[)() I.[)() 46(73.0) 
y~ 277 (38.6) 145 (33.3) 0.78 (O.61 ~ 1.00) 0.71 (O.5ol - D.92) 17 (27.0) 0,57 (0.32 _ 1,02) 0.52(0.29·0.95) 
p 0.01 0.06 0.03 
OR _ odds ra tio; NSA1Ds . non s tcroid~l .. nti-inthmmatory drug, 
• Adjusted for patient age and sex. 
I Multivariate adjustment for age, sex, body mass index, height. educ<ltion, fibre intake, calcium supplements, alcohol and 
coloreclalcancer screcning 
, Odds ratio estimated by multinomi,11 logistic regression model. 
:;; 
Table 4.5.3 The associ ,ltion between bod y m a~~ index and colorectal cancer p,ltients stratified by sex and the V600E BRAF mutation status of 
thei r tumour 
Controls BRAF Wllumour 11600£ BRAF tumour 
5" Exposure N(I. (%) N (I . (% ) Univariat",' \ 'Iuhivariate' .Vo.f" c! Univariale" Mullivariate! OR (95' " C/J 
BMJ(Kg/m ' ) 
,.;24.9 1.00 
Men 25 - 29.9 I.IJ (0.77 -1.66) 
,]0 1.92 0 .24 - 2.99) 
P-tnmd 
BMJ (Kg/m') 
,;:24.9 1.00 1.00 
Women 25-29.9 1.41 (067-2.99) 
,3D 1.19(0.48 - 2.94) 
['-trend 0.62 
OR _ odd~ ratio; HMI 
' Adjusted for,lge 
' 1 ... lu itivariate adjustment for age, diabete~, smoking, non steroidal anti-inflammatory drugs, eduCiltion, fibre int~ke, calcium supplement. 
colorectal cancer screening and height. Odds ratios for women were alw adjusted for hormone contraceptive ust', horomone replacement 
therapy and menopausal status 
00 
00 
Chapter 5 - Discussion 
5.1 Introduction 
The greiltest strength of this study is thilt it tilkes il multidisciplinilry ilnd 
molcculilr pilthology epidemiologicill ilpproilch to invcstig'lting the heredit'lry 
bilSis of colorectill Cil ncer in Newfoundlilnd. Another strength of this reseilrch 
project is thilt it hils recru ill'd illilrge number of incident ilnd populiltion-bilsed 
colorectal C,lncer pil tients, as well ilS a ];uge number of populiltion-bilst>d controls, 
which hils embled multivMiilte s tnt istics to be compu ted. 
ropulilti(ln-bn~ed studies offer ildv<Jn tilgcs over selected cohort stt ldics, 
pMticulilrly beCilUSC they ilre less susceptible to biases thilt Ciln ilffed the villidity 
and g{'l1l'ralizibility of st udy findings. Consequently, the find ings of this rl'scMch 
project Me likely to be highly generillizilble to s imilM piltient populil tions. They 
are also likely to be gener;;1lizablc from ;;1 molecular genet ics perspt.'Ctive, ilS 
Newfoundland has the best generalizibility to Caucas i<Jn populiltions when 
comp;lTed to twelve other founder populi1tions 181 
This s tudy also hilS severililimitations that should be noted , First, 
populiltion-bilscd studies arc s usCl'ptible to a non-Tl'sponder bias, particularly if il 
hi);h proportion of cli);ible pilt ients are not successfully recruited. The bias Mises 
from the fa ct that non-responders may be system<Jtically diffcrl'nt from 
Tt.'Sponders, which C,ln affect both the validity and gcneraliz ibility of findings 
That being said, the present study achieved a response rate (64%) that is g rea ter 
than what has been typically achieved by compMable population-based s tudies 
[288,289]. However, it should be cautione<\ thilt the study cohort cxdude(\ 
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patients who were diagnosed a t 75 years of age or greater, which may reduce the 
generalizibility of its findings to the population. St'cond, this analysis has madl' 
numerous comp<lrisons and it is possible th,lt some find ings arc due to ch<lnce It 
should also be noted that for some ,malyses st<llis tic<ll power W<lS limited by 
sm<lll sample size. Third, case-control studies are retrospt.'Ctive in nature and 
C<l nnot determine c<lusal ity, but there is rons icierable evidence to indic<lte Ih,l t 
diaoctes, smok ing and NSA [Ds exert caus,l l effecls with respert to colorectal 
carcinogenesis. Additionally, exposure dat<l was collected retrospectively and 
was *If-reported, which could putenti<llly reduce the internal v<llidity of this 
s tud y OCC,lUS.' of rerall bias. Fotlfth, althou gh the participation rate of controls 
(49%) was relatively high, responden ts differed from non-respondents 12901. 
Las tly, the New foundland <lnd L<lbr<ldor population may not be represent<llive of 
other populations; however as previously discllssed, from a molecular genetics 
pcrspt.'Ctive the NL population has the gre<ltest gener<l lizibility to C.uK<lsi<ln 
popu l<ltions [8] 
:1.1 Epidemio logy 
The microsate llite-inst<lbility phenotype is <l ssoci<lled with <l distinct pathway 
of colorec\a l C,lllcer carcinogenesis that occurs in approximately 15;;' of all 
tumours. [nthe prescnt study, II ;;' of colorcctaltumours were found to oc MSI-
H. The low proportion of MSJ-H tumours is likely explained by the f,lCt th'lt 
MS[-H is positively <lssociated with <lge <lml the present study h<ls excluded 
patients grea ter than 75 years of <lge at diagnosis. The micros,l tcll itc-inslabili ly 
phenotylX' is also strongly associated with Lynch syndrome and 28';:, percent of 
90 
,111 p,ltients who hild ,1 MSI-H tumour cilrried il pilthogenic vilr iilnt o f MLlf1, 
MSI-I2, MS/-/6 or PMS2 
The finding s fro m previous studies [1 99,209,2\0] estimate that between 100;;, 
and [8% of colorectil[ tumours are V600E mu tatiun pos itive. In the current study, 
the previllence o f the mutiltion (12%) occurred ,1t till' low end of this r,lngl', which 
is likely explained by the f.lCt that the V600E mutiltion is also pos itively 
associated with incre,lsi ng age. The mutation is also strongly ilssoci ated with 
MSI-H tumours ilnd it occurred in SO'f" of MSI-H tumours (n =' 38), but only in 8';:, 
of MSS tumours (n =' 27). 
A small proportion of piltien t ~ (3.0% of the study populiltiun) could not be 
stratified acconling to the molecular pathology of their tumours (shadt'd grey in 
Figure 2). The etiology uf thesc 17 patients who h<1d a MSI-BRA F WI tu mou r is 
unclear, <IS tht.'SC patients cou ld not be linked wi th eitht'r Lynch syndrome or the 
V600E mutation. Eight patients identified as "possible serrated pathway" had a 
tumuur that W<1S hypermethylated at the MUll promoter. As MLHI p romoter 
methylation is strongly associated with the sl'rrilkd pilthw,lY, thl'S(' pil tients 
li kely sh,lre ,1 s imilar etiology <IS piltients who hilve il MS[-V6OVE tumour. TIll' 9 
otht'f patients, identified as 'possible Lynch syndrome', l1<1d MSI- BRAF Wt 
tumors that were unmethylated <1t the MUD promoter. These tumours are, 
therefore, unlikely to be ilsoociated with epigenetic dysrt'guJa tion and the 
scrratt'J Jlt'oplasiil pilthway. However, since these tumours ilTe defi cient in at 
least one MMI{ protein on [HC, theS(' patients may be carrying a pathogenic 
MMR variant that was undetected by our methods. 
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There are two Jddi tionJI possibilities thJt mJY be responsible for our 
inconclusive findin gs. These molcculJr pJthology resuits for these pJticnts IllJy 
be related to J novel mechJnism of colorectJ! carcinogencsis, which results in the 
MSI- H phenotype without the inJctivJlion of MLHI, AlternJlively, these 
findings mJY be the result of J technic,ll fJilure or error 
5.3 Inherited ColorectaI Cancer 
ColorectJI CJncer is one of the most hereditary of Jllthe common 
mJlignJllCies. In the presen t study, 32'1<, of pJtients hJd JIl immediJte family 
member Jffected by colorectJI cancer and these patients were suspected of 
Iw ving inherited J predisposition to develop colorectJI cancer. Our definition of 
hereditMY colorectal CJ ncer did not include pJ tients who had J second-degree 
rdative affected by color",ct,,1 cancer - a knowll colorect,,1 CJ ncer risk factor 144J 
- Jnd, therefore, our estimJte of hereditary colorectal CJllcer mJY be 
conservative. The findin gs from twin and populJ tion-bJsed studies 111- I3J 
indica te that betwl'Cll 20% Jnd 30% of all colorectal cancer patients are 
ilttributable to inherited factors. Therefore, the findings of the present study 
suggest tha t the prevJlence of inherited colorectal CJncer in the Newfoundland 
population is high. The reJsons for this Me uncleJr, but it I1My be rdJted to 
greJler ellvironmentJI risk, founder effects in unidentified genes or better 
ilscerta inment of fil miliill risk. It mJy be JllributJble, in pMt, to NewfoundlJnd's 
founder poptllJtion and a hi gh prcvall'l1ce of mutJtiolls in known susceptibility 
gent·s (i.e. cilusing Lynch synd rome and familial "denomat{)us polypo,;is), but a 
recent anillysis by Woods ct a/1291 I indicates that this b llot the case Rather, 
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theSt:' findings suggl;'St that the high prevalence of hereditnry colorednl (nn(er in 
the NL populiltion is likely the rl'stdt of novel susceptibility fnctors, either 
goml;'tic, env ironnll;'ntnl or both. 
5 .. 11/ fig/I-Risk Patiel/ts 
Wel l-definl'd inherill'd colorectill CilnCl'r syndromes <He l'stim,lted 10 account 
for ilpproximiltely 5% of illl eRC patients, and Lynch syndrome accounts for the 
majority of these palil;'nts 1[1 51. Lynch syndrome was attributable for 3% of 
patien ts in this study populntion. Howl;'wr, npproximately 9% of the study 
population .,atisfied high-risk cri terion and g reater than two-thi rds of these 
patients wl;'re unrc!ilted to Lynch syndrome and hild iln unknown diology 
Approximiltely half of all p,ltients (56%) who satisfy the AC-l criteria are not 
affected by Lynch syndrome and h,we a microsatellite-stable tumour - meeting 
the criil'ria fo r FCCTX. This find ing is consis tent with othec population-based 
studies [37, 266, 267, 292], which havc found 40% of patients who satisfy the 
Amsterdam I critecia to have a microsatellite-stable tumour. 
The etiology of FCCiX is unknown and whether it is caused by highly 
pendrant gene mutations is unclear. There is, however, ilccum u lating evidence 
from genetic linkilge studies 127-32, 268, 293, 2941 indicilting th il t FCCrX is more 
likely to be caused by il number of low-to-moderately penetrilnt risk alleles, 
rilthec thiln ,1 single highly penetrilnt diseilse illlcle. In the prescnt study, the 
estimate of lifetime colorectill cancec cisk in FDRs of patiellts identified as FCCTX 
(l ifetime risk = 391<, ) is consistent with ,1 highly penetrant monogenic disease. 
However, aftec removal of the ilffected family members who were necessilrY to 
9] 
satisfy the Fccrx criteri,l, the estimate of rbk (lifctim(' risk "" 20%) is lower and 
no longer supportive of a highly penetrnnt monogenic disense. This finding is 
consis tent with one other studyl371 that has investigated the risk of colorectal 
C,lnccr associ"ted with rcax. Lindor ("/ a/[37J reported that thl' incidenCl' of 
colorecl,ll c"nCN in FCaX f"milies w"s sign ifi c"ntly less when compilrl'd to 
Lynch synd rome kind reds nnd that the risk of colorect"[ C,lnrer in family 
members of FCcrX p,ltients W,lS only moder;;ltely elevated (SIR = 2.7; 95% Cl, 1.9 
- 3...1). Our estimate of colorect,,1 cancer risk (Sll{ = 4.9; 95% 0, 2.3 - 9.4) is 
compilrable and provides further support for the argument that FCaX is 
unlikely to be cnused by n single highly penetrnnt vnri.1nt 
FCcrX patients h"ve been recognized to h,we" c1inicop"thologic"J profile 
thilt is distinct from thnt of Lynch syndrome pntients 137, 265·267, 2951. 
Consistent with thl'S(' olnit'Tv"tions, rco·x p"tients were diagnosed at.1 
sign ificantly later .1ge th.1n Lynch sy ndrome p.1tients (t' ;; 0.02) "nd had ,1 
sign ificantly reduced incidence of multiple tumours (I' ;; 0.04). In "ddition, 2 of 
15 (IYJ,, ) tumours from FCcrX patients contained the V600E BRAF mut,ltion "nd 
thus likely to be associated with the serrated neopl.1sia pathway, which is 
supportive of the suggestion that FCCTX represcnts a heterogenous disease 
The mean age of colorectal cancer diagnosis in FCcrX f,1Il1iiies h,lS 
consistently been found to be greater than 50 years of age 137, 265-267[ 
Therefore, it would appear that the age criterion of the Fccrx criteri.1 could limit 
the capacity to identify similar patients who have a family his tory suggestive of 
.1l1tosomal dominant disease. Thus, we intro..iuced the M-FCcrX criteria to 
remove the .1ge criterion of the FCCTX criteria (colorectal C,lllcer d i.lgnosed <50 
94 
ye.1rs of .1ge), in o rder to identify .1dditioml patients whose famil y histori t!S 
suggest dominant inherit.1nce, but who have a later age of onset. An additional 
16 (3.3'70 ) patients were identified and the clinicop.lthological profile of these 
p.1tients, as well as tht! cancer-risk in FDRs, was comparable to FCC rX. As 
expected, age at cancer d iagnosis in FDRs was slightly higher than in FCcrX 
families. However, after the age of 50 years the risk of colorecta l C.m ceT in FDRs 
of FCCTX and M-FCCTX p.1tients W.1S virtu.111y ident ical. These findings suggest 
th.1t the current FCCrX crite ri.11ack sensitivity to ident ify familit! ~ who ex hibit.1 
s tro ng su~cep lib ility 10 devclop colorec\al cancer. The FCC rX capture 
ap proximately 3',1., of the study population who have a severe but unknown 
J isease prt!disposition. However, by d iminating tht! rt!~ tr icti ve age-crite rion of 
the FCCTX criteria, an addit ional 3'70 o f the ~tudy population (i.e. 67-, in to t,11 ) 
fulfill s high-risk family hi~tory criteri.l (i.t!. M-FCCTX crite ria ). Although the 
num ber of p.l ti ent~ meeting dther the FCcrX or M-FCcrX criteria represents 
only a small proportion of patients, they represent double the number of Lynch 
syndrome pa tients 
95 
53.2 /llierllledilli,'·Risk Patil'llts 
The etiology of hereditary colorectal cancer is poorly understood Although 
multiple susceptibi lity loci have been iden tified, these variants exp lain li ttle of 
the excess familial risk. The findings of the presen t study, suggest that the 
prl'S('IlCt' of the V600E HRAF mutation and the occurrence of multiple tumours 
are associated w ith a 2-fold g reMer family h istory of colorectal ca ncer when 
compared to families of patit!nts without either of thes(' fl'altlres 
The V600E BRAF mutation is strongly associated with sessile serrated 
adenomas and appears to be a sensitive and specific moleCllla r marker of the 
sessilt! St!rrated adenoma neoplilsia pathway 1220J. [n thl' present study, the risk 
of developing colorectill cancer was significilntly devilted for famil y members of 
patients who had a V600E tumour. Compared to fam ily members of pa tients 
who had a solitary BRAF Wt tumour, the risk of developing colorecta l was 2.7-
fo ld g reater in family members of patients who had a V600E tumour. Given the 
strong association ~tween the V60UE mutilt ion and the SSA pathway, this 
finding may indicate ,h,lt SSA pilthway is associ ilted with iln elevilil'd colofect,11 
ca ncer ri sk for family members 
The serrated neoplasia pa thway is a relatively Ilew discovery r IH21 and its 
d iology is unclea r. However, the fi nd ings of the current study provide further 
support for the hypothesis that the serrated pathway has an inherited component 
r 184, IHSJ. The serrated pathway is linked to two Cilncer syndrollles associated 
with st'rratcd precursor lesions and colorectal cancer, namely hyperplastic 
polyposis syndrome and serr.lted p.lthw<lY syndrome I [85]. The fo rmer is a r.He 
polyposis syndrome that is ,lssociated with substantiill colofectill cancer risk and 
appears to be hereditary. The [,liter was described by Young 1'1 al [255], who 
provided evidence for an autosomiil dominant colorecta l cancer syndrome that i~ 
a~sociakd with the development of ad vanced ~errated lesions and with the 
development of MSI-variab[e, V6UOE HRAF, proximally [ocated tumours. There 
is ,lisa some evidence that clinical and molecular markers linked with the 
serrated pathway are associated with inherited colorectal cancer. An elev,lted 
family history of cancer has been observed in piltients who hilvt' proximillly 
located serrated polyps 12961, il V6UOE tumour [2 11, 255, 297-299[ or il ClMI'-
po~iti ve tu mOll r 11 99, 3001. However, the evidence is limited as most studies 
hilve been small or have used selected pill ient cohorts. To this ,m thor's 
knowledge, the present study is the larges t and mos t thorough investigation of 
the association between family history and V600E colorectal c,m cer. 
Patients who had BRAF Wt multiple tumours also had a significantly 
elevated family history of colorectal cancer. The incidcnce of colorectal canCt'r in 
family members is approximately 2-fo ld greakr reliltive to fam ily members of 
index pillients who Iwd a solitary BRAF \Nt tumour. The explanation for this 
finding is not immedi,ltely ilpparent. I lowever, it is highly unlikely to be due to 
known co!orcrta[ cancer syndromes (i.e. Lynch syndrome or polyposis 
syndromes), as these pillients were excluded from this particular analysis. It 
may, however, be explained by recent findin gs from colonoscopy sCfCC"n ing ilnd 
molt'Ctdar studies, which suggest that the development of a synchronous or 
mdachronous colorectal tumour may be associated wi th the se rrated p,lthway. 
For ex,lmple, the presence of a large or proximally [ocated serrated polyp is now 
recognized to be a strong risk factor for the develo pment of a synchronous Of 
mt;'ttlchronow; tumour [296, :)01, 3021 tlnd one study has suggested thtlt a IMge or 
proximally located serrated polyp is <I greilter risk f<lctor thiln the presl'llce of 
multiple tubulilf ildenomils. Molecul<lr studies [303-3051 ilre illso reporting thilt 
the development of multiple colorectal tumours is strongly <lssociated with 
features of the serrated p,lthway. such <IS aberr,lnt DN f\ methyl <l tion, the V6UUE 
lJRA F mutiltion and microsilte1 lite-instilbility. Additiontllly, it appt;'MS that the 
traditional serrated neoplasia pathway, which is characterized by ncoplasiil of 
tht;' distal colon [306, 307[, alterations of KRAS rilther thiln U/{AF ,1Ild with 
methylation of MGMT [303, 3051 Me strongly associated with the development of 
synchronous and Ilwtilchronous colort;'ctill nt;'oplasia. Unlike the association 
betwCC"n family history and piltients who hild il V60UE ttlmOr, the e levated 
familial predisposition observed with patients who had U/{AF WI multiple 
tumours may be attributable to the tr<ldition<l l st;'rr<l\ed adenoma neoplasia 
pathway 
P<ltients whose tumors cont,lined the V6VVE mut,ltion hild <l d istinct cl inical 
phenotype reliltive to p<ltients who had a BRAF Wt tumour. Patients with <l 
V6VV[ tumour were signific<lntly more likely to be female and to have ,1 
proxim'lily loc<ltt;'d tumour. Colorectal tumoucs that wece V60UE were ,llso 
associilted with a distinct his tologic<ll phenotype rela tive to BRAF \Vt tumours. 
V6VOE tumours were significantly more likely to be poorly differentiated, to 
contain tumouc-infiltrating lymphocytt;'s, and to have a mucinous component 
TheS!;' findings are consistent with St.'VCf,ll studies [UBI th<lt have reported V60UE 
colorect<ll cancer to be associated with a distinct clinic<ll, molt;'cul<lf, <lnd 
histological phenotype. Convers.ely, a synchronous or metachronou s tlllTIuur 
was not associated with any distinct clinical or histological feature. 
5.4 V600E Coloree/nl Callcer 
The V600E BRAF mutation is an early molecular event in the sessile serrated 
,1denoma pathway of carcinogenesis and it is undear if later events, such ,1S 
ep igenetic inactivation of MLI 11 and the microsatellite-instabil ity phenotype, 
influt;'nce tIlt;' c1 inicopathologocal phenotype and elevated familial cancer-risk 
observed in patients who have a V6UOE tumuur. The clinicopathologica l 
phenotype and cancer-risk associated with patients who have a V6OUl:: tumour 
was investigated according to the microsa tt;'llite-instability status of these p,ltient 
The findings suggest thilt V600E culoredal cancer is significantly associated 
with an elevated risk of colorectal cancer in family members irrespectivt;' of 
tumuur micmsatellite-instability status. The risk of developing coloredal <:;lnCt;'r 
was significa ntly elevated in family members of patients who had either ,1 MSS 
(l!R = 2. 19) or a MSI (HI{ = 1.75) V6UUE tumuu r. These findings suggest thill 
early molecular events in the sessilt;' serrated adenoma pathway of colorectal 
carcinogenesis may be linked with an devilled familial risk 
x'Vl'r,l l studies [211, 255, .108] have investigilled the associ,ltion between 
patients with a V6UOf tumour and a family history of cancer, but only one s tud y 
1211 ] has used a population-b,lscd i1pproilch. A correlation between ,1 f'lnlily 
history of coloredal cancer and patients with ,1 MS[-V6UUE [WAF tumou r has 
been prl'viously reported [JOR]. However, that particular study \308] used il 
sel~cted cohort of familial colort.'Clil l pilti~nts, ilnd only eight MSI tumours were 
eVilluilled. A populiltion-bilsed s tudy conducted by Silmowitz ct al [211]. 
reported finding il s ignificilnt ilssociiltion between piltients who hild il MSS-
V600E Uf{AF tumour ilnd a family history of colorectill cilnce r (OR = 4.23; 95~;, ct, 
1.65 - 10.84). However, no significilnt ilssociation W(lS found ilmongst piltients 
who had il MS1-H- V600E tumOllr (OR = 0.64; 95% Ci, 0.18 - 2.19). The findings of 
the present study Me the first to ft'port iln ilssociiltion bel\Vl'en p<l tients who h(lve 
a MS1-V600E tumour and il family his tory of colorectal cancer in an unsclccil'd 
se ries of population-based patients. 
It has been postulated [185] that the burden o f colorectal cancer arising from 
the serrated pathway could beexplainet.l by a co-dominant model. In a co-
domin,lnt model of inheritance, the more severe phenotype associated with H I'S 
may be the result of a carrier of two mutalt'd ill1des of the hypothesi;o:ed gene. 
The increilsed predisposition to develop sessile serr.1ted adenomas and serrated 
pathw,lY neoplilsia mily be ilttr ibu table to carriers of one mutated allele. 
The present s tud y investigated the mode of disease inheritance associa ted 
with the development of V6UOE colort;'(:t(ll cancer by comparing the risk of 
developing colorectal C.lncer in s iblings and parents. A far greater incidence of 
colorectal cancer in siblings compa red to p.lfents would be expected if inherited 
filctors Wefe transmitted in an autosomal recessive manner. Alternativcly, if the 
mode of disc(lsc inheritance were mul tif<lctori<ll o r autosomal dominant, one 
wou ld expect that the incidence of colorectal cancer to be comparable between 
pMenl::; (lnd s iblings. This analysis has made the ,1sSLImption that inherited 
variants plily il role in the etiology of V6()()E colorectal cancer, which may not be 
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true. Nevertheless, the findings of the prescnt study provide some evidencc for 
differen t modes of inherit.mce depending on the MSI s ta tu s of tht;' ind t;' x piltit;'nt's 
tllm our. In piltients who have a MSS-V600E BRAF tummlr, the incidence of 
co]orectal cancer was significantly greater in siblings than in parents; whereas the 
incidence was similar between parents and siblings for patients who had ,1 MSI-
V600E tumour. These findings may suggest that MSS-V600E BRAF (Olorect,ll 
canCt'T disease ~usceptibili ty is associated with recessively inheri ted factors; 
whl' reas the incidence of colorectal ("<l no,'T in filmilies of pillients who havt;' a MSI-
V600[ Bn.AF tumoUT was more suggestive of dominant or multi-factoriill 
inheritance. 
We investigated the incidence o f extril-colonic tumours in family members of 
index patients. Family mcmbers of index patients who had a V600E tumour had 
a significantly cleva ted incidence of non-mela noma skin GlIlct;' r compared to 
fami ly mt;'mbers of piltients who had a BRAF Wt tumor. Interestingly, the resu lts 
of ,1 recmt prospective study [309 [ found a 2-fold increase in the risk of colorectal 
cancl'r following a diagnosis of non-mdilnomil skin cancer. Colorectal and non-
melanoma skin cancer share some of the same risk filctors, such ,1S smokin,l; [246] 
Furthermore, susceptibili ty to develop both non-melanomil ski n Cilncer ilnd 
V600E colorectal cancer appears to be modified by the interilction betWt'en 
env ironmentil l exposures and polymorph isms in the bilse t;'xcision repai r genes, 
XRCCl and aCCl, respectively [248, 310]. A reCl'nl Cilst!-control study ]24Rl 
reported that t;'ver-smokers who were homozygous fo r Ill(' aCC1 (53260 
polymorphism were twice as likely to have a V600E tumour. The obst'rved 
association bctwecn V600E colorectal cancer and non -mel<lnoma skin callcer 
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observed in thl' present study might be explilined by ,1n inherited V.lri,lnt thilt 
would incrCilSC susceptibility to both types of Cil nccr by .. ttenunting DNA r~pair 
c,lp .. bili ty. 
The clinicopil thoJogicill phenotype of p,l til'nts who hild il V600E tumour was 
found to be dependent on microsatellite-inst .. bility stiltuS. Reg.lrdless of r.,·ISI 
StiltuS, piltients with il V600E tumour were significilntly more likely to be fl'l11ale 
,Irld to have a proximal tumour than p .. tients who hild a 8RAF Wf tumour. 
Howevl' r, piltients with a MSI tumour, but not those who hild il MSS tumour, 
were s ignificilntly older ilt diagnosis. This finding is consistent with the MSI 
phenotype tending to occur in tumors d iagnoscd later in life. Additionillly, 
pati~nts who h .. d a MSl tUlllou r wcre morc likdy to have mu ltiple tumou rs. 
These findings provide further evidcnce thilt V600E colorectill canc~r is 
ilssociatcd with il dis tinct clinicill, moleculilr ilnd pilthologic,ll phenotype [208, 
211,219] 
The V600E tnutiltion in microsiltellite-stilble colorl'ctill c,lncer has bt.'Cn 
identified 12111 ilS a milrker fo r poor prognos is. In tIll' preS\.'nt s tudy, pnti~nts 
who had il MSS-V600E tumour were s ignific'lntly mort' likely to bt' diilgnosl.'d ,1t 
il lilh:r disease stilg~ compilr~d to piltients who had a 8RAF WI tumour. 
Howcv~T, after multivari,lte ildjustment, this rt.'Sult was no longer s tatistically 
signific,lnt. Micros,ltellite-inslilbility is rccognizl'd ilS ,1 positive prognos ti c 
marker and piltients who had a MSI- V600E tumor wert' mort' likl'ly to be 
d iagnosed .. t an early s tage of diSl'ilS(' compilred to patients who had a MSS-
BRAF WI tumour. HoweveT, this rl'SUIt did not rl' ilCh sl illis ti cill s ignificance in 
multi vil riilteanil lysis. 
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Until recently there has bt'cn insufficient data to m,lke evidence-ba~d 
decis ions reg,lrding b('sl scrl'l'ning and surveillance for serrated lesions. It is now 
('vident 1296,301,3021 that serrall'd polyps, particularly large ,1nd proximally 
10C,11t:'d lesions, harbour substantial malignant potential. It is also now 
rt.'Cognized that the serrated pathway may be associall'd with 20% of colort.'Ctal 
ca ncers and with 30'70 of interval colorectal cancers 11831. These revelations have 
spurred recommendation for surv('illance guidelines to rt.'Cognize the importance 
and malignant potential of serrated polyps 131 [I. The findings of the current 
s tudy may also be relevant to future colorcctal cancer sCTCl'ning practices. Risk-
s tratification is an important facet of population-b,lscd colorectal cancer 
sCfct:'ning guidelincs, which utilize f'lmily his tory information to identify those at 
increased risk of colorectal cancer and to provide them with earlie r and more 
aggress ive scrt.'ening. In the current s tudy, fami ly members of colorect,ll cancer 
patients who had either a V600E or BRAF WI multiple tumours wc re twice as 
likely to develop colorectal cancer. These findings suggest that markers of the 
~rrated pathway could be ust'ful as markers of increa~d cancer risk in family 
members. Although this study is the largest and mos t thorough investigation of 
hereditary colorectal cancer and markers of the serr,lIed pathway to d.lil" its 
findings will nl~d to be validated by addition:!1 s tudies. Nevertheless, the 
findings suggest that markers of the ~rrated pathway could be utilized to 
iden tify famil ies who arc at increased risk of developing colorectal c,1I1cer :!nd 
who should be enrolled in high-risk scrcening progr,lms. 
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5.5 Epitfl'miofogicfl l FlIc to rs ,wd V600E Cofor.'c tlll ClIllcrr 
The dell'rmin<lnts <lnd consl'quences of insu lin resistance syndrome <Ire 
established colorect<ll c<lncer risk factors [61 1, bu t it is unclear if theS(' risk fa ctors 
are t!(lually involved with <llll'rn<ltive p<lthways of co]orl'ct<ll c<lrcinogenl'sis. The 
V600E BRAF mut<ltion in colorectal c,lncer has bt'!t!n linkt!d to <I nUlllber of 
lifestyle <lnd dil'lilTy f<lctors, including .1!ow-fiber diet [2371, smoking [237, 245-
2481 <lnd NSA IDs [2371, but the association between V600E colorect,ll cancer and 
diabt!tes has not lx-en investigakd. 
The findings of this <In<llysis indic<l te th<l t di<lbt! tt.~ <lnd silloking <l n~ strongly 
associ<lted with the risk of developing V600E colorectal C.lIlCCr. Ad d ition<llly, the 
regular use of NSAIDs is associatl>d w ith a significantly d iminisht.'<1 risk of 
developing V600E co!orecl<ll c<lncer. Thesc findings suggest th,lt met,lbo!ic 
derangement and inflam matory mechanisms may pl<ly <In import.lnt ro!e in the 
etiology of V600E colorectal c.lnccr ,11ld the sessile serrated adenoma pathway of 
carcinogenesIs 
SimililT to colorectal c.ucinogenesis, insulin resistance syndrome is a complL'x 
and hl'terogenolls disease that has numerous exogenollS and endogenous risk 
factors. Its pathology is believed to involve imp<lired insu lin s ign<lling through 
tht! PlK3 p<llhway, but with intact insulin signaling via the MAPK pathw,lY, 
which results in impa ired glucose uptake and systemic inf1arnm,lt ion [551. Till'sc 
abnormalities <HC also implicated with the p,lthology of cilTdiov.lscular discase, 
di<lbctt!s <lnd C<lnCt!r 
Di<lbctes is <I cliniC<l1 end-point of long standi ng Cl'lIular insulin resistance ,lIld 
is strongly associ<ltc-d with <In incre,lSl><l risk of developing coiorl'Ct<l1 cancer [61 [. 
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A recentmetihlnalysis suggests that diabetes incrcas(.'s the risk of developing 
colorectill C,ln(1.'[ by 30';;, (95'%, 0, 20% - 40';Q [63[. [n the present study, diabetes 
WilS significantly associated with the development of V600E colol"l.'ctill Cilncer 
This is the first study to repoftthil t diilbetes or any metabolic ilbnormalitics 
linked with insulin resistilnce syndrome b ilsoociilted with the development of 
V6QOE colorectill Cilncer. That being said, this fin d ing is supported by evidence 
indicilting thilt Inl,t,lbolic derangement mily b.' associilted with serraled pilthw'ly 
ncoplasia. For exnmple, V600E colorectal canccr is recognizt..'t:\ to be stron);ly 
ilssociilted with the proximililumour locntion [209[nnd diabclt:'S has consistently 
bt't.'n linked [58, 59, 312-3141 as il rbk factor for neoplasia of the proxi mal colon, 
but not for the dist,ll colon. One study [314], which prospectively ilWt'stigilted 
the risk of developing colorectal C,ln(('r in a cohort of post-menop,lusal diabetics, 
is pnrtiCl.ilarly relevant since the V600E BRAF colorectal cancer is strongly 
associated with older women who arc post-menopaus..ll. [n that study, the risk of 
colorectal Cilncer ilftcr four\t..'\.'11 ye;;Hs of observation lVilS significantly elevilted for 
the proximal colon (RR = 1.9; 95% 0, 1.3 - 2.6), but not for the distill colon (R R = 
t.t; 95% 0, 0.6 - 1.8) or for the rectum (RR = 0.8; 95'1<, CI, 0.4 - 1.6)_ 
Tht'fc is also evidence suggesting that serr,lted pilthway precu rsor it.'Sions are 
linked with biochemic'll and clinic,ll ilbnormil lities thai arc associil il'd wi th 
insulin resistance syndrome. First, the occurrence of hyperplastic polyps - the 
precursor les ions of the S(.'rrilted pnthway - Me ilssocialed wi th elevated serum 
concc'ntriltions of insulin and insulin-like growth filctor-t (1CF-I). In a cohort of 
conse(:utively ascertained colonoscopy patients, Yoshida l' t 11/[2391 found 
clt'V,lled serum insulin concenlriltions 10 be positively correlated with the 
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pr~St;'nce of hyperplils tic polyps. Mureover, thc correlation W,lS found to be 
s trongest for right-s ided hyp~rplilshc pulyps, which <Ir~ the polyps thilt <Ire most 
li kely to harbor the V600E BRAF mu lil tion. ~cond, it hilS il lso been repo rted 
[240, 24 t [ thilt ilC rOIl1l'galy, ,1 condition ch<lractl'rized by dcvilll'd plilsmil [GF- [, is 
associated with the development of hyperplilstic polyps and colorectJI cancer. 
Furthermore, tht> risk of d~veloping hyperplastic polyps in these p<lti~nts is 
positively corrdilted with insulin resistilnce, insulin, and [C F-1. Third, a re<:ent 
study [238] has r~ported thM Jdiposity in women, which is a st rong determinant 
of insu lin resis tance and d iJbetes, is posit ive ly associJ ted with the incidence of 
hyperplastic polyps. These findings, although not definitive, provide some 
ev idence that metaboli<: derangement may be associated with serrated pathway 
neoplasiil and are supportive of this study'S findings. 
Chronic inflammation is linked with the underly ing pathophysiology of 
insulin resistance [315 1, diJbetes [3161 and colorectal canCt'r [781. 11 is for this 
re<lson IhJt the regulJ r use of NSA IDs is Jssociated with J red uction in the risk of 
devdoping diabell>s [3171 and coloredal cancer [80[ viii its inhibitory effects on 
infl,lmmJtion. [n the current study, the regular use of NSAIDs was inve",el y 
ass()<:i<lted with the development of V600E colorectal c,1I1cer. The ,1ssociation 
betwt.'t;!n V600E coloreclJI CJncer Jnd NSA1Ds hJS been investigated in only 011C 
other s tudy [2371, wh ich repor ted a borderline s ignificant inverse associ,l tion (O l{ 
=' 0.7; 95% ( I, 0.5 ~ 1.0). Nevertheless, severill other stud ies hJve found the 
regula r use of NSA IDs to be inversely associilil'd wit h the development of 
<ldvana-d right-s ided serrated lesions !2J6] ilnd hyperplils tic polyps !72, 233) 
The findings of the present study suggest thilt inflammiltory ml'Ch<lnisms may 
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plJy J pJrticulJrly important role in serrJ!ed pathwJY neoplJsia. These findings 
Jre also con!>istent with the hypothesis r 197J thJ t chronic inflJ rn mJtion is the 
pathogenic mechJnism ca using dysreguiJtion of gene promoter methylJtion Jnd 
thc St.'rrJted pJthwJY of cJrcinogt:'nesis. 
Despite the proven effic,1CY of NSAIDs JS J colorl'ctJI C,lncer 
cl1l'mOpreventJtive, the United StJtes Preventative TJsk Force [79, RaJ does not 
support their regular use, arguing that the benefits do not outweigh the harms. It 
could be argued, however, tha t for the appropriate at-risk population the 
chl'moprcvcnl<ltivt:' benefits of NSA IDs could potentially outweigh the harms. 
The findings of the present study r<lise tht:' possibility that those predisposed 10 
scrr,l/('d pathway t1eopl<lsia could benefit from the cht:'rnoprevt:'nt<ltive use of 
NSA IDs. Furthermore, as the usc of salicylates therapy is also linked with 
improved gl ucoSt:' metabolism [31R], insulin sensitivity [319J and a reduced risk 
of diabetes [3 17[ the rationale for intervention with anti-inflaml1l,ltory drugs in 
these particular patients may be s trengthened 
This analysis provides further evidence that smoking is st rongly associ<lil'd 
with patients who have a V600E tumour. After multiv<lfiate ,ldjus tmcnt, current 
smoking was a strong ,11ld independent ri sk filctor for V600E colorectal cancer 
(OR = 2.35; 95/1" CI, 1.06 - 5.24). A subst,lIltial body of ('vidcnct:' 12491 has 
identified smoking as a risk fJctor for colorec\,li cancer. Ikcent iy, however, the 
<lsSl)ciation between smok ing and colorectal cancer has bE't'n recognizl'd to be 
gre<ltest for Ih,)se with hyperpl<lstic polyps [242, 243J Jnd for patients who h<lVl' a 
microsatellite-instJble [2-14, 2451, e lMP or V600E tumour [237, 245-2481. The 
ft;,as()n for the st rong Jssociation is uncle.u, but it may be relJted to a link found 
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[76,771 between smoking ,md increilsed epG islilnd ml'lhyl,ltion. The strl'ngth 
ilnd consistency of the ilssociillion found betwt'Cn theSt' molecu lilT illteriltions ilnd 
smoking provides support for thl' hypothesis thilt smoking plilP; .1 role in the 
etiology of the serrilted pilthway of c<lrcinogenesis. In light of the findings of the 
current study, whi ch suggest that the V600E mutiltion is strongly ilssociil ted with 
metilbolic dl' rilngement ilnd inflilmmation, this author is incl ined to posit that the 
s trong rela tionship thilt h,l S lx"'Cn observed behvl'Cn smo king ilnd the V6()()E 
J3 RIIF muta tion may be attr ibutable, in part, to the effect of smoking in 
altenuilting insulin sensitivity [320, 321 1, IGF-I [322j, ilnd increasing 
inflammation [3231. 
Adiposity is associated with iln increased risk of colorectal cancer via its 
ad verse effects on insulin sensitivity, inflammation, g rowth f,l(tors, and steroid 
hormonl'S [64, 651. Although one study 12381 h,l S recently !inkl'd ildiposity with 
the devdopmt'llt of hyperplastic polyps, the present s tud y foun d no evidence for 
an association between an eiev,lIed BM I and the developml'nt of V600E colorectal 
Cilncer in ei ther men (P trend = 0.36) or women (/' trend = 0.84). However, in 
piltients with a J3 RAF Wt tumour, an eJev,lled BMI W,l S found to be a s ignificant 
risk f.lCtor fo r men (/' trend = 0.02), but not for women (P trend = 0.30). The 
observed disparity between men ilnd women is consistent with the findings from 
a r(,((, llt meta-,malysis [66 1, for which il number of mechanisms have Ix .... n 
proposed [64, 65 1. 
The findings of this casc-control study may provide some insight into the 
unknown ei io logicil! basis of V600E colorectal cancer alld the serr,lted p.llhway \)f 
c.uci nogenesis. The findin gs suggest that the etiology of the scrriltcd nooplasia 
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P,lthWilY ilnd V600E colorcct,ll c,mcl'r mily be involved with mdilbolic ,11ld 
inflammatory mechanisms. Reports from other epidemiologica l studies would 
illso support this hypothesis, as serrated pilthway neopl,lsiil has bt.>en linked to 
environmental, dietary and biochemical fa ctors that are associ:ltcJ with insulin 
rcsistilnCl' sy ndrome, including ildiposity, smoking, diabetes, low-fiber diet, 
NSf\I Ds, insulin resistance, elevated insulin ilnd IGF-I. There is illso support fo r 
this hypothesis from a genetic ilssociiltion st ud y 1324J, which discovered scrriltcd 
pilthwily colorectal Cilncer piltil'nts (i. l'. CiMI' or MSJ-H tumours) to be ilssociilll'd 
with gene va riants thM are imp licated with insulin signaling and inflammatory 
pa thwilYs. These findings sugg~t that the etiological b,l Sis of the serr,l ted 
pathway may be associ:lted with t'nvironmental, lifestyle and genetic factors that 
converge on insulin signil ling ilnd inflilmll1il tory pilthwJYs. Additionillly, thl' 
findings of this case-control JnJlysis may be JppliC,lble to future colorectal CJncer 
sCf..ening, surveillanct' and prevention practices, as they suggest that individuills 
who are dia~ti c o r who smoke arc parti cula rly a t-risk fo r developing serra ted 
PJthWily neoplilsiil. 
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Chapter 6 - Summary of Fi ndings 
rhi~ reseilrch projl'ct h,lS til ken a transd isciplin,lry and molecular pathology 
epidemiology approach to investigating the etiology of heredit ilry coloredill 
cancer. The g reil test strengths of this ~tudy ilre its molecular pa thology approach 
and the successful recru itmen t of a large number of population-based patients 
ilnd controls 
The findings of this research project indicate that only a small proportion of 
patients are affected by Lynch syndrome (3';', ). However, there ,He additional 
p:lIients who ful fill high-risk fami ly history criteria (i.e. Amsterdam [ crite riil), 
but h,lVe an unknown etiology . The risk of colorectal cancer in filmily members 
of these patients (i.e. FCcrX) is substantiill; however, the risk is not suggl's tiVl' of 
being ca used by a highly pcnctr,mt autosomal dom inant disease il lle1e. 
Additiollillly, the findings of this research sugges t that the age cri te rion of the 
FCCTX criteria is overly rest rictive. By eliminilting the ilge criterion of the 
FCCTX cri teria add itional famil ies are identi fied who exhibit a s imila r cancer-risk 
profile as familil'S identified as FccrX 
In add ition to high-ri sk patients, 26% of non high-risk patients have at lea~t 
one FOR affected by colorecta l cancer. These intermediate-risk patients are 
significan tly associil ted wi th e ither ,1 V600E tumour or a m ulti p le tu mour, when 
compared to low-risk piltients. For piltients who had either a V600E I)/{AF 
tumour or il muliiplL' tumour the incidence of colorect,ll ca ncer in f'lm ily 
members WilS ilpproximately 2-fold greater compa red to patients who hild 
neither of these features. As both of these feiltures are ::otrongly linked w ith the 
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serrated pilthwily of cilrcinogenesis it provides support for the hypothesis th'lt 
the scrr.1ted pathw .. y h .. s a genetic component. However, our findings ,1lso 
suggest th .. t environment .. 1 fnctors pby .. role in the etiology of V600E colorect,ll 
CanITT ,1nd the Sl"SSile serTilted pilthw.1Y of c.lTcinogl'nl'Sis. The development of 
V600E colorectill Cilncer W,lS found to be significantly associ .. ted with diilbeks 
ilnd smoking. ,1nd inversdy associilted with the usc of NSAIDs. Thus, tht-'S(' 
findings suggest thilt the moleculilr etiology .lnd colorect,ll cancer susceptibility 
associated with the serrated p .. thway may be linked with endogenous and 
exogenous risk f .. ctors th .. t .. ffect insulin s ign .. ling ,md infl .. mmatory p .. thw .. ys. 
These findings of this rcscilrch may have relevance ilnd ilpplic.1tions to future 
(olore<:t,ll (,mcer screening and prevention practices. Clinic,l! and mole<:ular 
feiltures of the serrated p .. thwilY of carcinogenesis m .. y be useful markers of 
increased bllli!ia] risk, which m .. y .. id to identify fnmilies who should be 
emolled in high-risk colorcct.1l (,mITr s(rl'ening. Addition .. lly, the findings 
suggest thai those who are metabolically unfit and or who smoke may be 
particularly at-risk for developing serrated pathwilY ncoplasia 
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